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The synthesis of α-benzamido-α-benzyllactones 23 of various ring size was 
achieved either via ‘direct amide cyclization’ by treatment of 2-benzamido-2-benzyl-
ω-hydroxy-N,N-dimethylalkanamides 21 in toluene at 90–110° with HCl gas or by 
‘ring-transformation’ of 4-benzyl-4-(ω-hydroxyalkyl)-2-phenyl-1,3-oxazol-5(4H)-
ones under the same conditions. The precursors were obtained by C-alkylations of 4-
benzyl-2-phenyl-1,3-oxazol-5(4H)-one (15) with THP- or TBDMS-protected ω-
hydroxyalkyliodides. Ring opening of the THP protected oxazolones by treatment 
with Me2NH followed by deprotection of the OH group gave the diamides 21, 
whereas deprotection of the TBDMS series of oxazolones 25 with TBAF followed by 
treatment with HCl gas led to the corresponding lactones 23 in a one-pot reaction. 
 
 
 
 
Keywords: Lactones; 1,3-oxazol-5(4H)-ones; ring-transformation; direct amide 
cyclization
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1. Introduction. – Since the pioneering work of Erlenmeyer on the synthesis of 
azlactones [1], 1,3-oxazol-5(4H)-ones have been recognized as an important class of 
heterocycles [2]. Their synthesis, reactivity and use as intermediates in organic 
synthesis have been described in several reviews [3], and the continuing interest in the 
chemistry of 1,3-oxazol-5(4H)-ones is documented by a large series of recent 
publications (e.g. [4]). 
We became interested in 1,3-oxazol-5(4H)-ones as intermediates in the 
‘azirine/oxazolone method’ for the synthesis of peptides containing α,α-disubstituted 
α-amino acids [5][6]. It has been shown that peptides of type 1 with a C-terminal Aib-
amide on treatment with HCl in toluene at elevated temperature form 1,3-oxazol-
5(4H)-ones 2, which in the presence of nucleophiles spontaneously react under ring 
opening to give, e.g., esters 3 [6a,c,d] (Scheme 1). Furthermore, it was proposed that 
the DCC-coupling of peptides containing a terminal Aib-acid with amino acid esters 4 
leads to peptides 5 via an intermediate 1,3-oxazol-5(4H)-one 2 [6b–e] (cf. also 
[4e][7]). The smooth and selective cyclization to give 1,3-oxazol-5(4H)-ones may be 
explained by the Thorpe-Ingold (gem-dimethyl) effect [8]. 
 
Scheme 1 
 
In the case of Aib-amides of type 1 with an alcohol function in R1, the 
intermediate 2 undergoes a spontaneous ring enlargement reaction via nucleophilic 
attack of the OH group onto C(5)=O of 2 to give lactones of type 6 (Scheme 1) [9]. 
This reaction, called ‘direct amide cyclization’, has been used extensively for the 
synthesis of Aib-containing cyclodepsipeptides [9–11]. The same concept, under 
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different reaction conditions, proved to be successful for the preparation of Aib-
containing cyclopeptides [11][12]. 
It was also shown that amino acid derivatives of type 8 under the conditions of 
the ‘direct amide cyclization’ react to give 13 – 15-membered lactams 10, albeit in 
low yield (11–27%) [13] (Scheme 2). Most likely, 1,3-oxazol-5(4H)-ones 9 are 
formed as intermediates, which undergo a ring-transformation via nucleophilic attack 
of the amino group onto C(5)=O of 9. An analogous ring transformation has been 
described recently by Rai et al. [4g] (Scheme 2): Whereas 2-phenyl-1,3-oxazol-5(4H)-
one (11) and the tosylated aziridine 12 in the ionic liquid [bmim]OH at room 
temperature react to give the oxazolone derivative 13, the corresponding pyrrolidine 
14 was formed in the presence of I2 as a 96:4 mixture of cis/trans isomers. It has been 
shown that 13 is an intermediate, which undergoes ring-transformation to yield 14 by 
treatment with I2 in [bmim]OH at room temperature. 
 
Scheme 2 
 
Based on the results described above, it was of interest to study the ‘direct 
amide cyclization’ of compounds of type 8 bearing an OH instead of the NH2 group in 
the side chain as well as the corresponding ring-transformation of analogues of 9 with 
a (CH2)nOH group at C(4). Preliminary experiments with compounds 8 with a 
(CH2)nOH side chain were reported many years ago [14] (cf. also [11]). In the present 
report, we describe the extension of the study in detail together with the crystal 
structures of some of the prepared macrocyclic lactones. 
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2. Results and Discussion. – Motivated by the results of the preliminary study 
[14], we planned to prepare 1,3-oxazol-5(4H)-ones of type 17 with THP-protected 
alkanol substituents at C(4) (Scheme 3). The alkylation of 4-benzyl-2-phenyl-1,3-
oxazol-5(4H)-one (15) [15] with 2-[(ω-iodoalkyl)oxy]tetrahydropyranes 16 [16] in 
THF/HMPT with LDA at 15–20° led to mixtures of the desired C(4)-alkylated 1,3-
oxazol-5(4H)-ones 17 and the isomeric O-alkylated 1,3-oxazoles 18 (ratio ca. 2:1 to 
4:1)2). Unfortunately, all attempts to deprotect selectively the alcohol function were 
unsuccessful, and complex mixtures of products were formed. For this reason, the 
mixtures of 17 and 18 were treated with Me2NH in MeCN at room temperature. After 
chromatographic purification, the diamides 20 were obtained and subsequently 
deprotected by treatment with pyridinium tosylate (Py.TsOH) in boiling EtOH [17] to 
give compounds 21 in good yields. Finally, the ‘direct amide cyclization’ of 21b (n = 
11), i.e., treatment of a solution in toluene at reflux with HCl gas for ca. 2 h, gave the 
lactone 23b in 86% yield (with respect to 21b). Under the same reaction conditions, 
23a (n = 9) was obtained in only 43% yield. In addition, 4-benzyl-4-(9-
hydroxynonyl)-2-phenyl-1,3-oxazol-5(4H)-one – the proposed intermediate in the 
‘direct amide cyclization’ is the corresponding hydrochloride 22a (Scheme 3) – was 
isolated in 55% yield. Obviously, in this case, the reaction time was too short for 
complete conversion. 
 
                                                 
2)  In the case of the alkylation with 2-[(11-iodoundecyl)oxy]tetrahydropyran (16b), 
butyl 2-benzamido-2-benzyl-13-[(tetrahydropyran-2-yl)oxy]tridecanoate (19, 
11%) was isolated in addition to 17b/18b. 
 
Formula 19 
 6 
Scheme 3 
 
The structures of the products were confirmed from their spectroscopic data 
and by X-ray crystallography (Fig. 1). Since for both molecules the space group is 
centrosymmetric (P21/c), the compounds in the crystals are racemic. Furthermore, in 
the case of 23a, the benzyl group is disordered over two nearly equally occupied 
conformations. 
 
Fig. 1. ORTEP Plots [18] of the molecular structures of the 12- and 14-
membered lactones 23a (major conformation) and 23b (50% probability ellipsoids, 
arbitrary numbering of atoms) 
 
In summary, although the described protocol allows the synthesis of 14- and 
12-membered lactones 23, the reaction sequence via ring opening of 17, subsequent 
deprotection of 20, and cyclization via the oxazolone intermediate 22 is not very 
straightforward. Deprotection of the alcohol function in 17 followed by ring-
transformation to give the lactone would be a more attractive approach. Therefore, a 
different OH-protecting group was desired, which could be cleaved without 
destroying the oxazolone moiety in compounds of type 17.  
A suitable choice was the (tert-butyl)dimethylsilyl (TBDMS) group, which 
allows deprotection by treatment with F– ions [19]. The ω-bromoalkanols in DMF 
were treated with TBDMSCl and imidazole at 25° for 1.5 h leading to the O-protected 
derivatives in 81–99% yield [16]3).  The latter were transformed into the 
                                                 
3)  The desired O-protected ω-bromoalkanols were, in some cases, contaminated 
with variable amounts of the corresponding O-protected ω-chloroalkanols. 
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corresponding iodo compounds 24 by treatment with excess NaI in boiling acetone 
(Finkelstein reaction) [20]4). The subsequent alkylation of the 1,3-oxazolone 15 by 
using pure 12-{[(tert-butyl)dimethylsilyl]oxy}-1-iodododecane (24c, n = 12) under 
the conditions described for the THP-protected iodoalkanols 16 gave, after 
chromatographic workup, the azlactone 25c as a viscous oil in 35% yield (Scheme 4, 
Table 1)5). In a similar manner, 15 was alkylated by using the obtained ω-{[(tert-
butyl)dimethylsilyl]oxy}-1-iodoalkanes (24, n = 11, 10, 8–6, 3, 2)3). In all cases, 
mixtures of the corresponding C- and O-alkylated products 25 and 26 were formed, 
with the desired 25 as the major product, in some cases together with the 
corresponding butyl ester of type 27 (Table 1). Separation of the products by means of 
flash-chromatography (FC [21]) gave, in general, a mixture of 25 and 26, which was 
                                                 
4) For the halogen exchange, the obtained mixtures of bromo and chloro derivatives 
were used. Under the chosen reaction conditions, only the bromo compounds 
were transformed to the desired O-protected ω-iodoalkanols [16]. For the 
subsequent alkylations of oxazolone 15, mixtures of iodo and chloro derivatives 
were used. 
5)  In addition, a non-separable mixture of butyl and but-3-enyl 2-benzamido-2-
benzyl-14-{[(tert-butyl)dimethylsilyl]oxy}tetradecanoate (27c and 28c, resp., ca. 
4:1) was obtained. Their formation has been rationalized via nucleophilic ring 
opening of azlactone 25a by Li butanolate (BuOLi) and Li but-3-enolate, 
respectively. Small amounts of the latter are formed by the reaction of THF with 
BuLi/HMPT at –30 to 20° [16].  
 
Formula 27c/28c 
 8 
subsequently used for the ring-transformation reaction. Only in the case of 25i and 26i 
with the (CH2)2 side chain were the two products obtained as pure compounds. 
 
Scheme 4 
 
Table 1. Alkylations of 1,3-Oxazol-5(4H)-one 15 with ω-{[(tert-
Butyl)dimethylsilyl]oxy}-1-iodoalkanes 24a) (Scheme 4). 
 
The first experiments to deprotect the silylated primary alcohol group in 
compounds 25 by treatment with pyridinium fluoride were unsuccessful, but the 
deprotection was achieved with tetrabutylammonium fluoride (TBAF). Thus, 
bubbling HCl gas through a solution of 25c and TBAF.3 H2O in toluene at 90–110° 
for 1.5–2 h led directly to the 15-membered lactone 23c, which was isolated as a 
colorless crystalline material in 65% yield (Scheme 4). In one of the repetitions of the 
experiment, 35% of 23c were obtained side by side with 43% of 4-benzyl-4-(12-
hydroxydodecyl)-2-phenyl-1,3-oxazol-5(4H)-one, the proposed deprotected 
intermediate. Under acidic conditions (HCl), the corresponding hydrochloride 22c 
spontaneously underwent ring-transformation to give 23c. The expected structure of 
23c was supported by the spectroscopic and analytical data and finally established by 
an X-ray crystal-structure determination (Fig. 2). 
 
Fig. 2. ORTEP Plot [18] of the molecular structure of the 15-membered lactone 23c 
(major conformation; 50% probability ellipsoids, arbitrary numbering of atoms) 
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The space group of 23c (Pbca) is centrosymmetric and therefore the 
compound in the crystal is racemic. The 15-membered ring is disordered in such a 
way that both enantiomers are present at the same site. In this arrangement all atoms 
of the enantiomers occupy identical positions, with the only detectable difference 
being the presence of the lactone carbonyl O-atom on both sides of the quarternary C-
atom of the 15-membered ring.  The ratio of the site occupation factor of the 
disordered sites is approximately 10:1. The N-H group of each molecule acts as a 
donor for intermolecular H-bonds. The corresponding acceptor atom is the O-atom of 
the amide group of a neighboring molecule [N(1)–H….O(3’); H....O = 2.12(2) Å, N–
H….O 172(2)°]. These H-bonds link the molecules into extended chains which run 
parallel to the [001] direction and can be described by a graph set motif of C(4) [22]. 
Under the same reaction conditions, oxazolones 25b, d–h, used as mixtures 
with the corresponding oxazoles 26, as well as the pure oxazolone 25i, were 
transformed into the 14-, 13-, 11–9-, 6- and 5-membered lactones 23 (Scheme 4, Table 
2). The 6- and 5-membered lactones 23h and 23i were obtained in very good yields, 
and also the yields of the large-ring lactones 23b and 23c (14- and 15-membered, 
resp.) were good. As expected, the formation of the medium-sized rings was more 
difficult, and the products were isolated in fair-to-low yields, with the lowest one 
(10%) for the 11-membered lactone 23e. Furthermore, a comparison of the formation 
of the 14-membered lactone 23b via ‘direct amide cyclization’ of diamide 21b 
(Scheme 3) and via ‘ring transformation’ of 4-(11-hydroxyundecyl)-1,3-oxazol-5(4H)-
one 25b indicate that the first type of reaction is more efficient (86 vs 69% yield). 
 
Table 2. Synthesis of Lactones 23 via Ring-Transformation of Oxazolones 25a) 
(Scheme 4) 
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The structures of the racemic lactones 23d–23f were also established by X-ray 
crystallography (Fig. 3). In 23f, the amide NH group forms an intermolecular H-bond 
with the carbonyl O-atom of the lactone group of a neighboring molecule [N(1)–
H….O(1’); H….O = 2.32(2) Å, N–H….O = 150(2)°]. These interactions link pairs of 
molecules into centrosymmetric dimers. It is worth mentioning that in the crystal 
structures of 23a, b, d and e, the amide NH group is not involved in intermolecular H-
bonds. In all cases, the H-atom of the NH group is located close to the O-atom of the 
lactone C=O group, most likely resulting from geometric restriction rather than being 
real H-bonds. Furthermore, in all lactones except 23e, the Ph ring of the benzamido 
group is not coplanar with the NH–C=O group. 
 
Fig. 3. ORTEP Plots [18] of the molecular structures of the lactones 23d–23f 
(50% probability ellipsoids, arbitrary numbering of atoms) 
 
3. Conclusions. – The present study demonstrates that macrocyclic lactones of 
type 23 can be prepared in fair-to-good yields from 2-benzamido-2-benzyl-N,N-
dimethyl-ω-hydroxyalkanamides 21 by treatment with HCl gas in boiling toluene, i.e., 
via ‘direct amide cyclization’. This reaction occurs via formation of a 4-(ω-
hydroxyalkyl)-substituted 1,3-oxazol-5(4H)-one hydrochloride 22 as an intermediate, 
in analogy to the reaction of the corresponding ω-aminoalkanamides to give 
macrocyclic lactams [13]. The precursors 21 are accessible by C-alkylation of 4-
benzyl-2-phenyl-1,3-oxazol-5(4H)-one (15), subsequent ring opening with Me2NH, 
and deprotection of the THP-protected hydroxy group. Changing the protecting group 
of the primary alcohol to the TBDMS-group allows the direct transformation of the 
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1,3-oxazol-5(4H)-ones 25 to the lactones 23. In this case, the intermediate 22 is 
formed via F– mediated deprotection of the primary alcohol follwed by treatment with 
HCl gas in boiling toluene.  
These results extend the use of 1,3-oxazol-5(4H)-ones as reactive building 
blocks and intermediates in organic synthesis. Intramolecular reactions with a 
nucleophilic group attached to the amino acid residue at C(2) are the key step in the 
preparation of cyclopeptides [12] and cyclodepsipeptides [9][10] containing α,α-
disubstituted α-amino acids, in which the 1,3-oxazol-5(4H)-ones are formed as 
intermediates. On the other hand, the ‘direct amide cyclization’ of 2-acylamino acid 
N,N-dimethylamides of type 21 with a ω-amino- or ω-hydroxyalkyl substituent in α-
position leads to lactams and lactones, respectively, via an intermediate 1,3-oxazol-
5(4H)-one bearing the nucleophile-containing side chain at C(4). In the present study, 
1,3-oxazol-5(4H)-ones with a protected hydroxy group in the side chain at C(4) are 
used as starting materials for the first time. 
 
Acknowledgement. – We thank the analytical sections of our institute for 
spectra and analyses, and F. Hoffmann-La Roche AG, Basel, for financial support.  
 
Experimental part 
 
1. General. See [13][16]. Solvents were purified by standard procedures. TLC: 
Merck TLC glass plates, silica gel 60 F254. Flash column chromatography (FC [21]): 
silica gel 60 (Merck), 0.040–0.060 mm. M.p.: Mettler-FP-5 apparatus, uncorrected. 
IR Spectra: Perkin-Elmer-297 or 781 spectrometer, in CHCl3 (3% soln.) if not 
otherwise indicated. 1H- and 13C-NMR spectra: Bruker AC-300, Bruker ARX-300 or 
Bruker AM-400 spectrometer at 300 or 400 (1H) and 75.5 or 100 MHz (13C), 
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respectively, in CDCl3; multiplicities of 13C signals determined by the DEPT 
technique. ESI-MS: Finnigan TSQ-700 instrument; EI (70 eV) and CI (with 
isobutane): Finnigan SSQ-700 instrument; m/z (rel. %).  
General Procedure 1 (GP 1; Alkylation of 4-Benzyl-2-phenyl-1,3-oxazol-
5(4H)-one (15)). To a stirred soln. of LDA6) in THF/HMPT (ca. 2:1 to 4:1) at ca. –
78°, a THF soln. of 15 was added, followed by the O-protected ω-iodoalkanol7). 
Then, the temperature was increased to +15 to 20° and the mixture stirred for 5–16 h. 
The mixture was extracted with cold H2O (0°, 2×) and Et2O (2×) and dried (MgSO4). 
Separation of the products by FC (hexane/Et2O 98:2 to 3:2) gave mixtures of the 
desired oxazolones 17 or 25 (major product) and the O-alkylated oxazoles 18 or 26 as 
well as butyl and but-3-enyl esters of type 19, 27 and 28.  
General Procedure 2 (GP 2; Ring Opening of Oxazolones 17 with Me2NH). 
To a soln. of a mixture of 1,3-oxazol-5(4H)-one 17 and 1,3-oxazole 18 in MeCN at 
24°, condensed Me2NH was added. After stirring for 2–5 h at 22–25°, the crude 
mixture of 20 and 18 was purified by FC (Et2O/hexane 3:2) to give THP-protected 
diamide 20. 
General Procedure 3 (GP 3; Deprotection of the THP-ethers 20). A soln. of 
the protected alcohol 20 (1 equiv.) and pyridinium p-toluenesulfonate (Py.TsOH, 0.17 
equiv.) in EtOH was heated at reflux for 2 h. After cooling to 24°, the solvent was 
evaporated, the residue was dissolved in CH2Cl2, the soln. washed with sat. aq. 
Na2CO3 soln. (2×), and dried (MgSO4). After filtration and evaporation of the solvent, 
the product 21 was purified by FC (SiO2, Et2O).  
                                                 
6)  Either freshly prepared from BuLi and iPr2NH in THF or purchased from Fluka 
AG, Switzerland. 
7) In some cases, mixtures of ω-iodo and ω-chloro derivatives were used [16]. 
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General Procedure 4 (GP 4; Direct Amide Cyclization of 21). Dry HCl gas8) 
was bubbled through a 1.9 mM soln. of 21 in toluene at 90–110° for 1.5–2 h. Then, 
the solvent was evaporated and the crude product was purified by FC (SiO2, 
hexane/Et2O 4:1 to 1:1) to give lactone 23. 
General Procedure 5 (GP 5; Ringtransformation of 25). Dry HCl gas8) was 
bubbled through a 1.9 mM soln. of a mixture of 25 and 26 in toluene containing 1.7 
equiv. of tetrabutylammonium fluoride trihydrate (TBAF.3 H2O) at 90–110° for 1.5–2 
h. Evaporation of the solvent and FC of the residue (SiO2, hexane/Et2O 16:9 or 4:1) 
gave lactone 23. 
2. Alkylations of 4-Benzyl-2-phenyl-1,3-oxazol-5(4H)-one (15) [15]. 2.1. With 
2-[(9-Iodononyl)oxy]tetrahydropyrane (16a) [16]. According to GP1, a mixture of 15 
(0.578 g, 2.30 mmol) in THF (5 ml), LDA (2.80 mmol) in THF (6 ml) and HMPT (5 
ml), and 16a (0.980 g, 2.77 mmol) in THF (5 ml) gave an oily mixture of 4-benzyl-2-
phenyl-{9-[(tetrahydropyran-2-yl)oxy]nonyl}-1,3-oxazol-5(4H)-one (17a) and 4-
benzyl-2-phenyl-5-{9-[(tetrahydropyran-2-yl)oxy]nonyloxy}-1,3-oxazole (18a) (0.366 
g, 33%). 
Data of the mixture of 17a/18a (2.2:1): Rf (Et2O/hexane 1:1): 0.48. IR 
(CHCl3): 3060w, 3020w, 2930s, 2860s, 1815s, 1655s, 1450m, 1440m, 1320m, 1290m, 
1135m, 1120m, 1075m, 1060m, 1025s, 975m, 785s, 730s, 700s, 670s. CI-MS 
(isobutane): 478 (12, [M+1]+), 394 (11), 133 (100), 85 (19). Anal. calc. for C30H39NO4 
(477.65): C 75.12, H 8.62, N 2.92; found: C 74.99, H 8.52, N 2.74. 
Data for 17a: 1H-NMR (300 MHz, CDCl3): 7.90–7.80 (m, 2 arom. H); 7.55–
7.45 (m, arom. H); 7.45–7.35 (m, 3 arom. H); 7.35–7.25 (m, arom. H); 7.20–7.10 (m, 
3 arom. H); 4.57 (dd-like, J ≈ 6.9, 3.8, OCHO); 3.95–3.80 (m, OCHeq); 3.71 (td, J = 
                                                 
8) HCl gas was bubbled through conc. H2SO4. 
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6.9, 9.5, 1 H of CH2O); 3.55–3.45 (m, OCHax); 3.36 (dt, J = 6.7, 9.6, 1 H of CH2O); 
3.21, 3.13 (AB, J = 13.3, PhCH2); 2.05–1.95 (m, 2 H); 1.90–1.75 (m, 2 H); 1.80–1.65 
(m, 2 H); 1.60–1.45 (m, 8 H); 1.45–1.15 (m, 8 H). 13C-NMR (50 MHz, CDCl3): 179.6 
(s, C=O); 159.6 (s, C=N); 139.3, 134.3  (2s, 2 arom. C); 132.3 (d, arom. CH); 130.0 
(d, 2 arom. CH); 128.5 (d, 2 arom. CH); 127.9 (d, 2 arom. CH); 127.6 (d, 2 arom. 
CH); 126.9 (d, arom. CH); 98.6 (d, OCHO); 74.7 (s, C(4)); 67.4, 62.1 (2t, 2 CH2O); 
43.7 (t, PhCH2); 37.3, 30.6, 29.6 (3t, 3 CH2); 29.2 (t, 2 CH2); 29.1, 29.0, 26.0, 25.4, 
23.9, 19.5 (6t, 6 CH2). 
Selected data of 18a: 1H-NMR (300 MHz, CDCl3): 7.95–7.90 (m, 2 arom. H); 
7.60–7.55 (m, arom. H); 4.10 (t, J = 6.6, CH2O); 3.84 (s, PhCH2). 13C-NMR (50 MHz, 
CDCl3): 129.3 (s, arom. C); 128.4 (d, 2 arom. CH); 128.2 (d, 2 arom. CH); 128.1, 
127.7, 125.6 (3d, 5 arom. CH); 98.6 (d, OCHO); 74.6 (t, CH2O); 31.0, 29.5, 29.4, 
28.9, 26.1, 25.53 (6t, CH2); 25.45 (t, 2 CH2); 25.3 (t, CH2). 
2.2. With 2-[(11-Iodoundecyl)oxy]tetrahydropyrane (16b) [16]. According to 
GP1, a mixture of 15 (2.000 g, 7.96 mmol) in THF (20 ml), LDA (9.60 mmol) in THF 
(30 ml) and HMPT (20 ml), and 16b (3.670 g, 9.60 mmol) in THF (20 ml) gave an 
oily mixture of 4-benzyl-2-phenyl-{11-[(tetrahydropyran-2-yl)oxy]undecyl}-1,3-
oxazol-5(4H)-one (17b) and 4-benzyl-2-phenyl-5-{11-[(tetrahydropyran-2-
yl)oxy]undecyloxy}-1,3-oxazole (18b) (1.584 g, 39%) as well as butyl 2-benzamido-2-
benzyl-13-[(tetrahydropyran-2-yl)oxy]tridecanoate (19, 0.631 g, 11%). 
Data of the mixture of 17b/18b (15:4): Rf (Et2O/hexane 1:1): 0.51. IR 
(CHCl3): 3060w, 3010m, 2930s, 2860s, 1815s, 1655s, 1495m, 1465m, 1455m, 1440m, 
1350m, 1320m, 1290m, 1135m, 1120m, 1075s, 1025s, 970m, 895m, 700s. CI-MS 
(isobutane): 506 (100, [M+1]+), 422 (23), 85 (13). Anal. calc. for C32H43NO4 (505.70): 
C 76.00, H 8.57, N 2.77; found: C 76.01, H 8.63, N 2.90. 
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Data for 17b: 1H-NMR (300 MHz, CDCl3): 7.90–7.80 (m, 2 arom. H); 7.55–
7.50 (m, arom. H); 7.45–7.35 (m, 2 arom. H); 7.25–7.10 (m, 5 arom. H); 4.57 (dd-like, 
J ≈ 4.3, 2.6, OCHO); 3.90–3.85 (m, 1H of CH2O); 3.72 (dtd, J = 11.7, 6.9, 4.1, 
OCHeq); 3.55–3.45 (m, 1 H of CH2O); 3.45–3.30 (m, OCHax); 3.21, 3.13 (AB, J = 
13.4, PhCH2); 2.05–1.10 (m, 13 CH2). 13C-NMR (50 MHz, CDCl3): 179.6 (s, C=O); 
159.6 (s, C=N); 134.3 (s, arom. C); 132.8 (d, arom. CH); 130.0 (d, 2 arom. CH); 128.5 
(d, 2 arom. CH); 127.9 (d, 2 arom. CH); 127.6 (d, 2 arom. CH); 127.0 (d, arom. CH); 
125.3 (s, arom. C); 98.6 (d, OCHO); 74.7 (s, C(4)); 67.5, 62.1 (2t, 2 CH2O); 43.7 (t, 
PhCH2); 37.3, 30.7, 29.6 (3t, 3 CH2); 29.3 (t, 5 CH2); 29.1, 26.1, 25.4, 23.9, 19.5 (5t, 
5 CH2). 
Selected data of 18b: 1H-NMR (300 MHz, CDCl3): 7.95–7.90 (m, 2 arom. H); 
7.35–7.25 (m, 2 arom. H); 4.11 (t, J = 6.6, CH2O); 3.84 (s, PhCH2). 13C-NMR (50 
MHz, CDCl3): 139.5 (s, arom. C); 129.3 (d, 2 arom. CH); 128.2 (d, 2 arom. CH); 
128.0 (d, 2 arom. CH); 126.0 (d, 2 arom. CH); 125.6 (d, arom. CH); 98.6 (d, OCHO); 
74.6 (t, CH2O); 31.0, 25.5 (2t, CH2). 
Data of 19: IR (CHCl3): 3410w, 3005m, 2930s, 2860m, 1725m, 1660s, 1515s, 
1485m, 1465m, 1455m, 1440m, 1350m, 1240m, 1200m, 1130m, 1075m, 1030m, 
705m. 1H-NMR (300 MHz, CDCl3): 7.75–7.65 (m, 2 arom. H); 7.50–7.45 (m, arom. 
H); 7.45–7.35 (m, 2 arom. H); 7.20–7.15 (m, 3 arom. H); 7.05–7.00 (m, 2 arom. H); 
6.97 (s, NH); 4.57 (dd, J = 4.3, 2.8, OCHO); 4.27, 4.13 (2td, J = 6.6, 10.8 and 6.5, 
10.8, resp., CH2OC=O); 3.93, 3.17 (AB, J = 13.5, PhCH2); 3.90–3.80, 3.55–3.45 (2m, 
CH2O); 3.72, 3.37 (2td, J = 6.9, 9.6 and 6.7, 9.6, resp., CH2O); 2.85–2.75 (m, 1 H); 
2.00–1.85 (m, 1 H); 1.85–1.15 (m, 14 CH2); 0.99 (t, J = 7.4, Me). 13C-NMR (50 MHz, 
CDCl3): 173.5 (s, OC=O); 166.5 (s, NC=O); 136.4, 135.3 (2s, 2 arom. C); 131.2 (d, 
arom. CH); 129.6 (d, 2 arom. CH); 128.5 (d, 2 arom. CH); 128.0 (d, 2 arom. CH); 
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126.7 (d, 3 arom. CH); 98.7 (d, OCHO); 67.6 (t, CH2O); 66.4 (s, C–N); 65.7 (t, 
CH2OC=O); 62.2 (t, CH2O); 40.6 (t, PhCH2); 35.3, 30.7, 30.5, 29.7 (4t, 4 CH2); 29.43 
(t, 2 CH2); 29.38 (t, 3 CH2); 29.3 (t, 2 CH2); 26.1, 25.4, 24.3, 19.6, 19.1 (5t, 5 CH2); 
13.6 (q, Me). CI-MS (isobutane): 580 (5, [M+1]+), 538 (3), 496 (100).  
2.3. With 12-[(tert-Butyl)dimethylsilyloxy]-1-iodododecane (24c) [16]. 
According to GP1, a mixture of 15 (0.395 g, 1.57 mmol) in THF (3.8 ml), LDA (1.57 
mmol) in THF (2.5 ml) and HMPT (2.5 ml), and 24c (0.836 g, 1.96 mmol) in THF 
(2.5 ml) gave 4-benzyl-4-(12-{[(tert-butyl)dimethylsilyl]oxy}dodecyl)-2-phenyl-1,3-
oxazol-5(4H)-one (25c) (0.300 g, 35%) as an oil and 0.141 g (ca. 14%) of a non-
separable mixture of butyl and but-3-enyl 2-benzamido-2-benzyl-14-{[(tert-
butyl)dimethylsilyl]oxy}tetradecanoate (27c and 28c, resp.). 
Data of 25c: Rf (Et2O/hexane 1:1): 0.67. IR (CHCl3): 3060w, 2930s, 2860s, 
1810s, 1655s, 1470m, 1460m, 1450m, 1320m, 1290m, 1255m, 1095m, 1045m, 970m, 
895m, 840s, 700s. 1H-NMR (300 MHz, CDCl3): 7.85–7.80 (m, 2 arom. H); 7.55–7.50 
(m, arom. H); 7.45–7.40 (m, 2 arom. H); 7.20–7.15 (m, 5 arom. H); 3.59 (t, J = 6.6, 
CH2O); 3.22, 3.14 (AB, J = 13.3, PhCH2); 2.05–1.95, 1.55–1.45 (2m, 2 CH2); 1.25–
1.10 (m, 9 CH2); 0.89 (s, Me3C); 0.04 (s, Me2Si). 13C-NMR (50 MHz, CDCl3): 179.7 
(s, C=O); 159.7 (s, C=N); 134.3 (s, arom. C); 132.3 (d, arom. CH); 130.1 (d, 2 arom. 
CH); 128.6 (d, 2 arom. CH); 128.0 (d, 2 arom. CH); 127.7 (d, 2 arom. CH); 127.0 (d, 
arom. CH); 125.7 (s, arom. C); 74.8 (s, C(4)); 63.2 (t, CH2O); 43.8 (t, PhCH2); 37.4, 
32.8, 29.6 (3t, 3 CH2); 29.5 (t, 2 CH2); 29.4 (t, 3 CH2); 29.2 (t, CH2); 25.9 (q, Me3C); 
25.7, 24.0 (2t, 2 CH2); 18.3 (s, Me3CSi); –5.4 (q, Me2Si). CI-MS (isobutane): 551 
(100, [M+1]+), 493 (17). Anal. calc. for C34H51NO3Si (549.88): C 74.27, H 9.35, N 
2.55; found: C 74.26, H 9.62, N 2.71. 
 17 
Data of the mixture of 27c/28c (3.8:1): Rf (Et2O/hexane 1:1): 0.55. IR 
(CHCl3): 3410w, 3000w, 2930s, 2860s, 1725m, 1660s, 1515s, 1485m, 1470m, 1460m, 
1440m, 1255m, 1200m, 1095m, 840s, 705m.  
Data of 27c: 1H-NMR (300 MHz, CDCl3): 7.70–7.65 (m, 2 arom. H); 7.50–
7.45 (m, arom. H); 7.45–7.35 (m, 2 arom. H); 7.20–7.15 (m, 3 arom. H); 7.05–7.00 
(m, 2 arom. H); 6.97 (br.s, NH); 4.35–4.30, 4.30–4.10 (2m, CH2O); 3.93, 3.17 (AB, J 
= 13.5, PhCH2); 3.59 (t, J = 6.6, CH2OSi); 2.85–2.75 (m, 1 H); 2.00–1.90 (m, 1 H); 
1.75–1.65 (m, 2 H); 1.60–1.40 (m, 5 H); 1.40–1.15 (m, 17 H); 0.99 (t, J = 7.3, Me); 
0.89 (s, Me3C); 0.04 (s, Me2Si). CI-MS (isobutane): 625 (100, [M+1]+), 567 (18), 105 
(44).  
Selected data of 28c: 1H-NMR (300 MHz, CDCl3): 6.94 (s, NH); 5.90–5.70 
(m, CH=); 5.50–5.51 (m, CH2=); 3.92 (A of AB, J = 13.5, 1 H of PhCH2); 2.55–2.45 
(m, 1 H). CI-MS (isobutane): 623 (29, [M+1]+). 
2.4. With 11-[(tert-Butyl)dimethylsilyloxy]-1-iodoundecane (24b) [16]. 
According to GP1, a mixture of 15 (0.330 g, 1.31 mmol) in THF (2 ml), LDA (1.31 
mmol) in THF (3 ml) and HMPT (2 ml), and 24b (0.650 g, 1.58 mmol) in THF (2 ml) 
gave 4-benzyl-4-(11-{[(tert-butyl)dimethylsilyl]oxy}undecyl)-2-phenyl-1,3-oxazol-
5(4H)-one (25b) and 4-benzyl-2-phenyl-5-(11-{[(tert-butyl)dimethylsilyl]oxy}-
undecyloxy)-1,3-oxazole (26b) (0.360 g, 52%). 
Data of the mixture of 25b/26b (9:1): Rf (Et2O/hexane 1:1): 0.64. IR (CHCl3): 
3010w, 2935s, 2860s, 1815s, 1660m, 1455m, 1290m, 1255m, 1095m, 1045m, 840s, 
700s. CI-MS (isobutane): 536 (100, [M+1]+). Anal. calc. for C33H49NO3Si (535.85): C 
73.93, H 9.22, N 2.61; found: C 73.87, H 9.29, N 2.79. 
Data for 25b: 1H-NMR (300 MHz, CDCl3): 7.85–7.80 (m, 2 arom. H); 7.55–
7.50 (m, 3 arom. H); 7.25–7.15 (m, 5 arom. H); 3.59 (t, J = 6.6, CH2O); 3.22, 3.14 
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(AB, J = 13.4, PhCH2); 2.05–1.95, 1.55–1.45 (2m, 2 CH2); 1.30–1.20 (m, 8 CH2); 0.89 
(s, Me3C); 0.04 (s, Me2Si). 13C-NMR (50 MHz, CDCl3): 179.7 (s, C=O); 159.7 (s, 
C=N); 134.4 (s, arom. C); 132.3 (d, arom. CH); 130.1 (d, 2 arom. CH); 128.5 (d, 2 
arom. CH); 128.0 (d, 2 arom. CH); 127.7 (d, 2 arom. CH); 127.0 (d, arom. CH); 125.8 
(s, arom. C); 74.8 (s, C(4)); 63.2 (t, CH2O); 43.8 (t, PhCH2); 37.4, 32.8, 29.5 (3t, 3 
CH2); 29.4 (t, 4 CH2); 29.2 (t, CH2); 25.9 (q, Me3C); 25.7, 24.0 (2t, 2 CH2); 18.3 (s, 
Me3CSi); –5.3 (q, Me2Si). 
Selected data of 26b: 1H-NMR (300 MHz, CDCl3): 7.95–7.90 (m, 2 arom. H); 
7.35–7.25 (m, 3 arom. H); 4.11 (t, J = 6.6, CH2O); 3.84 (s, PhCH2).  
2.5. With 10-[(tert-Butyl)dimethylsilyloxy]-1-iododecane (24d) [16]. 
According to GP1, a mixture of 15 (0.542 g, 2.09 mmol) in THF (3.2 ml), LDA (2.09 
mmol) in THF (5 ml) and HMPT (3.2 ml), and 24d (1.000 g, 2.51 mmol) in THF 
(3.22 ml) gave an oily mixture of 4-benzyl-4-(10-{[(tert-
butyl)dimethylsilyl]oxy}decyl)-2-phenyl-1,3-oxazol-5(4H)-one (25d) and 4-benzyl-2-
phenyl-5-(10-{[(tert-butyl)dimethylsilyl]oxy}decyloxy)-1,3-oxazole (26d) (0.662 g, 
60%) as well as but-3-enyl 2-benzamido-2-benzyl-12-{[(tert-
butyl)dimethylsilyl]oxy}dodecanoate (28d) (0.110 g, 9%). 
Data of the mixture of 25d/26d (10:1): Rf (Et2O/hexane 1:1): 0.63. IR 
(CHCl3): 3065w, 2940s, 2860s, 1815s, 1660s, 1500m, 1470m, 1465m, 1455m, 1325m, 
1290m, 1260m, 1045m, 1025m, 840s, 700s. CI-MS (isobutane): 523 (100, [M+1]+). 
Anal. calc. for C32H47NO3Si (521.81): C 73.66, H 9.08, N 2.68; found: C 73.46, H 
9.14, N 2.44. 
Data for 25d: 1H-NMR (300 MHz, CDCl3): 7.90–7.80 (m, 2 arom. H); 7.55–
7.50 (m, arom. H); 7.45–7.35 (m, 2 arom. H); 7.20–7.10 (m, 5 arom. H); 3.58 (t, J = 
3.6, CH2O); 3.21, 3.14 (AB, J = 13.4, PhCH2); 2.05–1.95, 1.55–1.40 (2m, 2 CH2); 
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1.35–1.10 (m, 7 CH2); 0.88 (s, Me3C); 0.04 (s, Me2Si). 13C-NMR (50 MHz, CDCl3): 
179.7 (s, C=O); 159.7 (s, C=N); 134.4 (s, arom. C); 132.3 (d, arom. CH); 130.1 (d, 2 
arom. CH); 128.5 (d, 2 arom. CH); 128.0 (d, 2 arom. CH); 127.7 (d, 2 arom. CH); 
127.0 (d, arom. CH); 125.7 (s, arom. C); 74.8 (s, C(4)); 63.2 (t, CH2O); 43.8 (t, 
PhCH2); 38.4, 37.4, 32.8, 29.5, 29.4 (5t, 5 CH2); 29.3 (t, 2 CH2); 25.9 (q, Me3C); 25.7, 
24.0 (2t, 2 CH2); 18.3 (s, Me3CSi); –5.3 (q, Me2Si). 
Selected data of 26d: 1H-NMR (300 MHz, CDCl3): 7.95–7.90 (m, 2 arom. H); 
4.11 (t, J = 6.6, CH2O); 3.83 (s, PhCH2); 3.60 (t, J = 6.6, CH2OSi). 13C-NMR (50 
MHz, CDCl3): 129.3 (d, arom. CH); 128.3 (d, 2 arom. CH); 127.8 (d, arom. CH); 
125.7 (d, 2 arom. CH); 125.4 (d, arom. CH); 29.65, 29.59 (2t, CH2). 
Data of 28d: Rf (Et2O/hexane 1:1): 0.57. IR (CHCl3): 3060w, 3010m, 2940s, 
2860s, 1730m, 1660s, 1520s, 1485s, 1470m, 1255m, 1200m, 1095m, 835s, 705m. CI-
MS (isobutane): 595 (100, [M+1]+). 1H-NMR (300 MHz, CDCl3): 7.70–7.65 (m, 2 
arom. H); 7.50–7.35 (m, 3 arom. H); 7.20–7.15 (m, 3 arom. H); 7.10–7.00 (m, 2 arom. 
H); 6.94 (br.s, NH); 5.90–5.75 (m, CH=); 5.20–5.10 (m, CH2=); 4.35–4.25, 4.20–4.10 
(2m, CH2OC=O); 3.92, 3.16 (AB, J = 13.5, PhCH2); 3.58 (t, J = 6.6, CH2OSi); 2.85–
2.75 (m, 1 H); 2.50–2.45 (m, CH2); 2.00–1.90 (m, 1 H); 1.55–1.15 (m, 16 H); 0.89 (s, 
Me3C); 0.04 (s, Me2Si).  
2.6. With 8-[(tert-Butyl)dimethylsilyloxy]-1-iodooctane (24e) [16]. According 
to GP1, a mixture of 15 (0.389 g, 1.55 mmol) in THF (3.5 ml), LDA (1.9 mmol) in 
THF (3.5 ml) and HMPT (2.4 ml), and 24e (0.700 g, 1.89 mmol) in THF (2 ml) gave 
4-benzyl-4-(8-{[(tert-butyl)dimethylsilyl]oxy}octyl)-2-phenyl-1,3-oxazol-5(4H)-one 
(25e) and 4-benzyl-2-phenyl-5-(8-{[(tert-butyl)dimethylsilyl]oxy}octyloxy)-1,3-
oxazole (26e) (0.445 g, 58%) as an oily mixture. 
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Data of the mixture of 25e/26e (8:1): Rf (Et2O/hexane 1:1): 0.60. IR (CHCl3): 
3060w, 2930s, 2860s, 1815s, 1655s, 1470m, 1465m, 1450m, 1320m, 1290m, 1255m, 
1095s, 1050m, 1020m, 1010m, 970m, 840s, 700s. CI-MS (isobutane): 495 (5, 
[M+1]+), 302 (100). Anal. calc. for C30H43NO3Si (493.76): C 72.98, H 8.78, N 2.84; 
found: C 73.21, H 8.98, N 2.91. 
Data for 25e: 1H-NMR (300 MHz, CDCl3): 7.85–7.80 (m, 2 arom. H); 7.55–
7.50 (m, arom. H); 7.45–7.35 (m, 2 arom. H); 7.20–7.10 (m, 5 arom. H); 3.57 (t, J = 
6.6, CH2O); 3.21, 3.14 (AB, J = 13.3, PhCH2); 2.05–1.95, 1.55–1.45 (2m, 2 CH2); 
1.45–1.20 (m, 5 CH2); 0.88 (s, Me3C); 0.03 (s, Me2Si). 13C-NMR (50 MHz, CDCl3): 
179.7 (s, C=O); 159.7 (s, C=N); 134.4 (s, arom. C); 132.3 (d, arom. CH); 130.1 (d, 2 
arom. CH); 128.5 (d, 2 arom. CH); 128.0 (d, 2 arom. CH); 127.7 (d, 2 arom. CH); 
127.0 (d, arom. CH); 125.7 (s, arom. C); 74.8 (s, C(4)); 63.1 (t, CH2O); 43.8 (t, 
PhCH2); 37.4, 32.7, 29.3 (3t, 3 CH2); 29.2 (t, 2 CH2); 25.9 (q, Me3C); 25.6, 24.0 (2t, 2 
CH2); 18.3 (s, Me3CSi); –5.3 (q, Me2Si). 
Selected data of 26e: 1H-NMR (300 MHz, CDCl3): 7.95–7.90 (m, 2 arom. H); 
7.35–7.25 (m, 2 arom. H); 4.10 (t, J = 6.6, CH2O); 3.84 (s, PhCH2); 3.60 (t, J = 6.5, 
CH2O).  
2.7. With 7-[(tert-Butyl)dimethylsilyloxy]-1-iodoheptane (24f) [16]. According 
to GP1, a mixture of 15 (0.588 g, 2.34 mmol) in THF (3 ml), LDA (3.5 mmol) in THF 
(8 ml) and HMPT (5 ml), and 24f (1.000 g, 2.81 mmol) in THF (3 ml) gave an oily 
mixture of 4-benzyl-4-(7-{[(tert-butyl)dimethylsilyl]oxy}heptyl)-2-phenyl-1,3-oxazol-
5(4H)-one (25f) and 4-benzyl-2-phenyl-5-(7-{[(tert-butyl)dimethylsilyl]-
oxy}heptyloxy)-1,3-oxazole (26f) (0.464 g, 42%) as well as butyl 2-benzamido-2-
benzyl-9-{[(tert-butyl)dimethylsilyl]oxy}nonanoate (27f) (0.173 g, 14%). 
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Data of the mixture of 25f/26f (23:4): Rf (Et2O/hexane 1:1): 0.62. IR (CHCl3): 
3060w, 2935s, 2860s, 1815s, 1655s, 1495m, 1470m, 1460m, 1450m, 1320m, 1290m, 
1255m, 1095s, 1050m, 1005m, 970m, 890m, 840s, 700s. EI-MS: 479 (12, M+), 251 
(19), 115 (13), 105 (100). Anal. calc. for C29H41NO3Si (479.73): C 72.61, H 8.61, N 
2.92; found: C 72.71, H 8.49, N 2.88. 
Data for 25f: 1H-NMR (300 MHz, CDCl3): 7.85–7.80 (m, 2 arom. H); 7.55–
7.50 (m, arom. H); 7.45–7.35 (m, 2 arom. H); 7.15–7.10 (m, 5 arom. H); 3.56 (t, J = 
6.6, CH2O); 3.21, 3.13 (AB, J = 13.3, PhCH2); 2.10–1.95 (m, CH2); 1.50–1.00 (m, 5 
CH2); 0.89 (s, Me3C); 0.02 (s, Me2Si). 13C-NMR (50 MHz, CDCl3): 179.8 (s, C=O); 
159.8 (s, C=N); 139.6, 134.6 (2s, 2 arom. C); 132.4 (d, arom. CH); 130.1 (d, 2 arom. 
CH); 128.6 (d, 2 arom. CH); 128.1 (d, 2 arom. CH); 127.8 (d, 2 arom. CH); 127.1 (d, 
arom. CH); 74.9 (s, C(4)); 63.2 (t, CH2O); 43.8 (t, PhCH2); 37.4, 32.7, 29.4, 29.1 (4t, 
4 CH2); 26.0 (q, Me3C); 25.6, 24.0 (2t, 2 CH2); 18.3 (s, Me3CSi); –5.3 (q, Me2Si). 
Selected data of 26f: 1H-NMR (300 MHz, CDCl3): 7.95–7.90 (m, 2 arom. H); 
4.10 (t, J = 6.6, CH2O); 3.81 (s, PhCH2); 3.60 (t, J = 6.4, CH2O); 0.89 (s, Me3C); 0.05 
(s, Me2Si). 13C-NMR (50 MHz, CDCl3): 129.4 (s,  arom. C); 128.6 (s, 2 arom. C); 
128.3 (s, arom. C); 125.4 (s, C=N); 74.7 (t, CH2O); 31.1, 29.4, 29.1, 26.1, 25.7, 25.0 
(6t, 6 CH2). 
Data of 27f: Rf (Et2O/hexane 1:1): 0.55. IR (CHCl3): 3410w, 3060w, 3020w, 
3005w, 2930s, 2860s, 1725m, 1660s, 1515m, 1485m, 1470m, 1320m, 1255m, 1095s, 
840s, 700m. 1H-NMR (300 MHz, CDCl3): 7.70–7.65 (m, 2 arom. H); 7.50–7.45 (m, 
arom. H); 7.45–7.35 (m, 2 arom. H); 7.20–7.15 (m, 3 arom. H); 7.05–7.00 (m, 2 arom. 
H); 6.97 (br.s, NH); 4.30–4.20, 4.15–3.95 (2m, CH2O); 3.93, 3.16 (AB, J = 13.5, 
PhCH2); 3.65–3.55 (m, CH2OSi); 2.85–2.80 (m, 1 H); 2.00–1.90 (m, 1 H); 1.70–1.60 
(m, CH2); 1.55–1.25 (m, 6 CH2); 0.96 (t, J = 7.4, Me); 0.88 (s, Me3C); 0.03 (s, Me2Si). 
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13C-NMR (50 MHz, CDCl3): 173.5 (s, C=O); 166.4 (s, NC=O); 136.4, 135.3 (2s, 2 
arom. C); 131.2 (d, arom. CH); 129.6 (d, 2 arom. CH); 128.6 (d, 2 arom. CH); 128.4 
(d, 2 arom. CH); 126.7 (d, 3 arom. CH); 66.4 (t, CH2O); 65.7 (s, C–N); 63.1 (t, 
CH2O); 40.6 (t, PhCH2); 35.3, 32.7, 29.3, 29.2, 28.9, 28.4 (6t, 6 CH2); 25.9 (q, Me3C); 
25.6, 24.3 (2t, 2 CH2); 18.2 (s, Me3CSi); –5.4 (q, Me2Si). EI-MS: 497 (12, [M–57]+), 
463 (8), 105 (75). Anal. calc. for C33H51NO4Si (553.86): C 71.57, H 9.28, N 2.53; 
found: C 70.62, H 9.89, N 2.32.  
2.8. With 6-[(tert-Butyl)dimethylsilyloxy]-1-iodohexane (24g) [16]. According 
to GP1, a mixture of 15 (0.490 g, 1.95 mmol) in THF (5 ml), LDA (1.95 mmol) in 
THF (5 ml) and HMPT (3 ml), and 24g (0.800 g, 2.34 mmol) in THF (5 ml) gave an 
oily mixture of 4-benzyl-4-(6-{[(tert-butyl)dimethylsilyl]oxy}hexyl)-2-phenyl-1,3-
oxazol-5(4H)-one (25g) and 4-benzyl-2-phenyl-5-(6-{[(tert-butyl)dimethylsilyl]-
oxy}hexyloxy)-1,3-oxazole (26g) (0.270 g, 30%) as well as butyl 2-benzamido-2-
benzyl-8-{[(tert-butyl)dimethylsilyl]oxy}octanoate (27g) (0.133 g, 13%). 
Data of the mixture of 25g/26g (20:3): Rf (Et2O/hexane 1:1): 0.64. IR (CHCl3): 
3060w, 3020w, 3000w, 2935s, 2860s, 1810m, 1655s, 1495m, 1470m, 1460m, 1450m, 
1320m, 1290m, 1255s, 1095s, 1050m, 1025m, 1005m, 990m, 965m, 840s, 810m, 700s, 
665m, 630m. CI-MS: 466 (100, [M+1]+). Anal. calc. for C28H39NO3Si (465.71): C 
72.22, H 8.44, N 3.01; found: C 72.18, H 8.66, N 3.22. 
Data for 25g: 1H-NMR (300 MHz, CDCl3): 7.90–7.80 (m, 2 arom. H); 7.60–
7.45 (m, arom. H); 7.45–7.35 (m, 2 arom. H); 7.20–7.10 (m, 5 arom. H); 3.55 (t, J = 
6.5, CH2O); 3.21, 3.13 (AB, J = 13.3, PhCH2); 2.05–1.95, 1.55–1.50  (2m, 2 CH2); 
1.50–1.10 (m, 3 CH2); 0.87 (s, Me3C); 0.02 (s, Me2Si). 13C-NMR (50 MHz, CDCl3): 
179.6 (s, C=O); 159.7 (s, C=N); 134.3 (s, arom. C); 132.2 (d, arom. CH); 130.0 (d, 2 
arom. CH); 128.5 (d, 2 arom. CH); 128.0 (d, 2 arom. CH); 127.7 (d, 2 arom. CH); 
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127.0 (d, arom. CH); 125.7 (s, arom. C); 74.8 (s, C(4)); 63.0 (t, CH2O); 43.7 (t, 
PhCH2); 37.3, 32.6, 29.2 (3t, 3 CH2); 25.9 (q, Me3C); 25.4, 23.9 (2t, 2 CH2); 18.2 (s, 
Me3CSi); –5.4 (q, Me2Si). 
Selected data of 26g: 1H-NMR (300 MHz, CDCl3): 7.95–7.90 (m, 2 arom. H); 
7.35–7.25 (m, 2 arom. H); 4.10 (t, J = 6.6, CH2O); 3.83 (s, PhCH2); 3.60 (t, J = 6.5, 
CH2O); 0.89 (s, Me3C); 0.05 (s, Me2Si). 13C-NMR (50 MHz, CDCl3): 129.3 (s, arom. 
C); 128.3, 127.84, 127.78, 126.7, 126.1, 125.3 (6d, 10 arom. CH); 74.5 (t, CH2O); 
31.1, 29.3 (2t, 2 CH2). 
Data of 27g: Rf (Et2O/hexane 1:1): 0.56. IR (CHCl3): 3410w, 3060w, 3000m, 
2935s, 2860s, 1730m, 1660s, 1530m, 1517s, 1487s, 1470m, 1460m, 1390m, 1350m, 
1285m, 1255s, 1200m, 1100s, 840s, 705s, 670m. 1H-NMR (300 MHz, CDCl3): 7.70–
7.65 (m, 2 arom. H); 7.50–7.45 (m, arom. H); 7.45–7.35 (m, 2 arom. H); 7.20–7.15 
(m, 3 arom. H); 7.05–7.00 (m, 2 arom. H); 6.97 (br.s, NH); 4.30–4.20, 4.15–4.10 (2m, 
CH2O); 3.93, 3.16 (AB, J = 13.5, PhCH2); 3.56 (t, J = 6.6, CH2OSi); 2.90–2.75 (m, 1 
H); 2.05–1.95 (m, 1 H); 1.80–1.70 (m, 2 H); 1.55–1.40 (m, 4 H); 1.40–1.25 (m, 6 H); 
0.99 (t, J = 7.3, Me); 0.88 (s, Me3C); 0.03 (s, Me2Si). CI-MS: 541 (100, [M+1]+), 105 
(25).  
2.9. With 3-[(tert-Butyl)dimethylsilyloxy]-1-iodopropane (24h) [16]. 
According to GP1, a mixture of 15 (0.709 g, 2.82 mmol) in THF (4.5 ml), LDA (2.70 
mmol) in THF (6.8 ml) and HMPT (4.5 ml), and 24h (1.049 g, 3.49 mmol) in THF 
(4.5 ml) gave an oily mixture of 4-benzyl-4-(3-{[(tert-butyl)dimethylsilyl]oxy}propyl)-
2-phenyl-1,3-oxazol-5(4H)-one (25h) and 4-benzyl-2-phenyl-5-(3-{[(tert-
butyl)dimethylsilyl]oxy}propyloxy)-1,3-oxazole (26h) (0.477 g, 40%) as well as butyl 
2-benzamido-2-benzyl-5-{[(tert-butyl)dimethylsilyl]oxy}pentanoate (27h) (0.222 g, 
16%). 
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Data of the mixture of 25h/26h (13:4): Rf (Et2O/hexane 1:1): 0.59. IR 
(CHCl3): 3060w, 3005w, 2960s, 2930s, 2890m, 2860m, 1815s, 1657s, 1495m, 1470m, 
1460m, 1450m, 1320m, 1290m, 1260s, 1040m, 1025m, 970m, 945m, 890m, 840s, 
810m, 700s, 670m. CI-MS: 424 (100, [M+1]+), 366 (20). Anal. calc. for C25H33NO3Si 
(423.63): C 70.88, H 7.85, N 3.31; found: C 70.84, H 8.04, N 3.51. 
Data for 25h: 1H-NMR (300 MHz, CDCl3): 7.85–7.80 (m, 2 arom. H); 7.55–
7.50 (m, arom. H); 7.45–7.30 (m, 2 arom. H); 7.20–7.05 (m, 5 arom. H); 3.60 (t, J = 
6.3, CH2O); 3.23, 3.15 (AB, J = 13.4, PhCH2); 2.10–2.00, 1.60–1.35  (2m, 2 CH2); 
0.87 (s, Me3C); 0.02 (s, Me2Si). 13C-NMR (50 MHz, CDCl3): 179.7 (s, C=O); 159.8 
(s, C=N); 134.4 (s, arom. C); 132.5 (d, arom. CH); 130.1 (d, 2 arom. CH); 128.6 (d, 2 
arom. CH); 128.1 (d, 2 arom. CH); 127.8 (d, 2 arom. CH); 127.1 (d, arom. CH); 125.4 
(s, arom. C); 74.6 (s, C(4)); 62.5 (t, CH2O); 43.7 (t, PhCH2); 33.9, 27.4 (2t, 2 CH2); 
25.9 (q, Me3C); 18.3 (s, Me3CSi); –5.4 (q, Me2Si). 
Selected data of 26h: 1H-NMR (300 MHz, CDCl3): 7.95–7.85 (m, 2 arom. H); 
4.24 (t, J = 6.3, CH2O); 3.83 (s, PhCH2); 3.75 (t, J = 6.0, CH2O). 13C-NMR (50 MHz, 
CDCl3): 129.6 (s, arom. C); 129.2, 128.8, 128.5, 128.4, 127.9, 125.7 (6d, 10 arom. 
CH); 125.5 (s, arom. C); 71.6, 59.1 (2t, 2 CH2O); 45.9 (t, PhCH2). 
Data of 27h: Rf (Et2O/hexane 1:1): 0.55. IR (CHCl3): 3405w, 3005m, 2960s, 
2935s, 2860m, 1725s, 1660s, 1520s, 1470m, 1450m, 1390m, 1350m, 1285m, 1255s, 
1200s, 1100s, 840s, 705w. 1H-NMR (300 MHz, CDCl3): 7.75–7.60 (m, 2 arom. H); 
7.60–7.35 (m, 3 arom. H); 7.30–7.00 (m, 5 arom. H); 6.95 (br.s, NH); 4.35–4.20, 
4.20–4.05 (2m, CH2OC=O); 3.89, 3.20 (AB, J = 13.4, PhCH2); 3.75–3.50 (m, 
CH2OSi); 2.85–2.70 (m, 1 H); 2.20–2.00 (m, 1 H); 1.80–1.65 (m, CH2); 1.65–1.40 (m, 
1 H); 1.40–1.20 (m, 1 H); 0.96 (t, J = 7.4, Me); 0.85 (s, Me3C); 0.00 (s, Me2Si). CI-
MS: 498 (100, [M+1]+), 440 (18), 105 (27).  
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2.10. With 2-[(tert-Butyl)dimethylsilyloxy]-1-iodoethane (24i) [16]. According 
to GP1, a mixture of 15 (0.309 g, 1.23 mmol) in THF (2 ml), LDA (1.20 mmol) in 
THF (3 ml) and HMPT (2 ml), and 24i (0.414 g, 1.45 mmol) in THF (2 ml) gave pure 
4-benzyl-4-(2-{[(tert-butyl)dimethylsilyl]oxy}ethyl)-2-phenyl-1,3-oxazol-5(4H)-one 
(25i) (0.305 g, 61%) and pure 4-benzyl-2-phenyl-5-(2-{[(tert-butyl)dimethylsilyl]-
oxy}ethoxy)-1,3-oxazole (26i) (0.048 g, 10%) as viscous oils. 
Data of 25i: Rf (Et2O/hexane 1:1): 0.48. IR (CHCl3): 3060w, 3020w, 2935w, 
2860w, 1820m, 1655m, 1470w, 1450w, 1320w, 1290w, 1255m, 1225m, 1205s, 1110m, 
1095m, 1020m, 980w, 895w, 835m, 780s, 670s. 1H-NMR (300 MHz, CDCl3): 7.95–
7.90 (m, 2 arom. H); 7.60–7.55 (m, arom. H); 7.55–7.45 (m, 2 arom. H); 7.25–7.20 
(m, 5 arom. H); 3.75–3.65 (m, CH2O); 3.26, 3.19 (AB, J = 13.3, PhCH2); 2.60–2.45 
(m, 1 H); 2.23 (dt, J = 2.9, 13.9, 1 H); 0.85 (s, Me3C); 0.00, –0.11 (2s, Me2Si). 13C-
NMR (50 MHz, CDCl3): 179.5 (s, C=O); 160.3 (s, C=N); 134.1 (s, arom. C); 132.2 
(d, arom. CH); 130.3 (d, 2 arom. CH); 128.5 (d, 2 arom. CH); 127.9 (d, 2 arom. CH); 
127.6 (d, 2 arom. CH); 127.0 (d, arom. CH); 126.2 (s, arom. C); 71.6 (s, C(4)); 58.8 (t, 
CH2O); 44.4 (t, PhCH2); 39.9 (t, CH2); 25.6 (q, Me3C); 18.0 (s, Me3CSi); –6.0 (q, 
Me2Si). CI-MS: 410 (100, [M+1]+), 352 (77), 324 (39), 289 (27), 250 (10). Anal. calc. 
for C24H31NO3Si (409.60): C 70.38, H 7.63, N 3.42; found: C 70.12, H 7.30, N 3.19. 
Data of 26i: Rf (Et2O/hexane 1:1): 0.58. IR (CHCl3): 3060w, 3030w, 2960m, 
2935m, 1740m, 1680m, 1480m, 1470m, 1260s, 1225m, 1205s, 1130m, 1105m, 930m, 
840m, 755s (br), 670s. 1H-NMR (300 MHz, CDCl3): 7.85–7.80 (m, 2 arom. H); 7.35–
7.25 (m, 3 arom. H); 7.25–7.15 (m, 4 arom. H); 7.15–7.05 (m, arom. H); 4.10 (t-like, J 
≈ 5.0, CH2O); 3.80 (t-like, J ≈ 5.0, CH2OSi); 3.76 (s, PhCH2); 0.82 (s, Me3C); 0.00 (s, 
Me2Si). CI-MS: 410 (100, [M+1]+). Anal. calc. for C24H31NO3Si (409.60): C 70.38, H 
7.63, N 3.42; found: C 70.21, H 7.50, N 3.29. 
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3. Ring Opening of Oxazolones 17 with Me2NH. 3.1. N-{1-Benzyl-1-(N,N-
dimethylcarbamoyl)-10-[(tetrahydropyran-2-yl)oxy]decyl}benzamide (20a). A 
mixture of oxazolone 17a and oxazole 18a (0.200 g, 0.42 mmol of 17a) dissolved in 
MeCN (13 ml) was treated with Me2NH according to GP 2 to give 0.193 g (89%) of 
20a as a colorless oil. Rf (Et2O/hexane 1:1): 0.12. IR (CHCl3): 3250w, 3060w, 3005m, 
2930s, 2860m, 1655m, 1625s, 1505s, 1480s, 1455m, 1440m, 1395m, 1120m, 1075m, 
1030m, 700m. 1H-NMR (300 MHz, CDCl3): 8.00 (br. s, NH); 7.60–7.80 (m, 2 arom. 
H); 7.50–7.35 (m, 3 arom. H); 7.20–7.10 (m, 3 arom. H); 7.05–6.95 (m, 2 arom. H); 
4.55 (dd-like, J ≈ 4.4, 2.7, OCHO); 4.12, 3.21 (AB, J = 14.3, PhCH2); 3.90–3.80 (m, 
OCHeq); 3.71 (td, J = 6.9, 9.6, 1 H of CH2O); 3.55–3.40 (m, OCHax); 3.36 (dt, J = 6.7, 
9.6, 1 H of CH2O); 3.40–2.90 (m, 2 H, Me2N); 2.05–1.00 (m, 10 CH2). 13C-NMR (50 
MHz, CDCl3): 171.0 (s, O=CNMe2); 165.7 (s, PhC=O); 136.6, 135.6  (2s, 2 arom. C); 
131.0 (d, arom. CH); 129.5 (d, 2 arom. CH); 128.3 (d, 2 arom. CH); 127.9 (d, 2 arom. 
CH); 126.7 (d, 2 arom. CH); 126.6 (d, arom. CH); 98.7 (d, OCHO); 67.4, 62.1 (2t, 2 
CH2O); 65.9 (s, C–N); 38.6 (t, PhCH2); 38.4 (q, Me2N); 33.6, 30.7, 29.6, 29.4 (4t, 4 
CH2); 29.3 (t, 2 CH2); 29.2, 26.1, 25.4, 24.2, 19.6 (5t, 5 CH2). CI-MS (isobutane): 523 
(<5, [M+1]+), 439 (24), 349 (100), 347 (10), 85 (14). Anal. calc. for C32H46N2O4 
(522.73): C 73.53, H 8.87, N 5.36; found: C 73.30, H 8.65, N 5.16. 
3.2. N-{1-Benzyl-1-(N,N-dimethylcarbamoyl)-12-[(tetrahydropyran-2-
yl)oxy]dodecyl}benzamide (20b). A mixture of oxazolone 17b and oxazole 18b (1.026 
g, 2.03 mmol of 17b) dissolved in MeCN (50 ml) was treated with Me2NH according 
to GP 2 to give 1.110 g (88%) of 20b as a colorless oil. Rf (Et2O/hexane 1:1): 0.12. IR 
(CHCl3): 3350m, 3060w, 3005s, 2930s, 2860s, 1660s, 1630s, 1580m, 1505s, 1480s, 
1455m, 1445m, 1400s, 1250m, 1120m, 1075m, 1030s, 700m. 1H-NMR (300 MHz, 
CDCl3): 7.99 (br. s, NH); 7.75–7.70 (m, 2 arom. H); 7.50–7.35 (m, 3 arom. H); 7.20–
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7.15 (m, 3 arom. H); 7.05–7.00 (m, 2 arom. H); 4.57 (dd-like, J ≈ 4.4, 2.8, OCHO); 
4.13, 3.22 (AB, J = 14.2, PhCH2); 3.90–3.85 (m, OCHeq); 3.72 (td, J = 6.9, 9.6, 1 H of 
CH2O); 3.55–3.45 (m, OCHax); 3.37 (td, J = 6.7, 9.6, 1 H of CH2O); 3.45–2.85 (m, 
Me2N); 2.00–1.15 (m, 13 CH2). 13C-NMR (50 MHz, CDCl3): 171.0 (s, O=CNMe2); 
165.6 (s, PhC=O); 136.5, 135.6  (2s, 2 arom. C); 131.0 (d, arom. CH); 129.4 (d, 2 
arom. CH); 128.3 (d, 2 arom. CH); 127.9 (d, 2 arom. CH); 126.6 (d, 2 arom. CH); 
126.5 (d, arom. CH); 98.6 (d, OCHO); 67.5, 62.1 (2t, 2 CH2O); 66.0 (s, C–N); 38.6 (t, 
PhCH2); 38.4 (q, Me2N); 33.6, 30.6, 29.6 (3t, 3 CH2); 29.4 (t, 5 CH2); 29.2, 26.0, 25.3, 
24.2, 19.5 (5t, 5 CH2). CI-MS (isobutane): 552 (47, [M+1]+), 467 (100), 422 (53), 105 
(44), 85 (35). Anal. calc. for C34H50N2O4 (550.80): C 74.14, H 9.15, N 5.09; found: C 
74.04, H 9.29, N 5.31. 
4. Deprotection of the THP-ethers 20. 4.1. N-[1-Benzyl-1-(N,N-
dimethylcarbamoyl)-10-hydroxydecyl]benzamide (21a). According to GP 3 a soln. of 
20a (0.170 g, 0.33 mmol) in EtOH (4 ml) was treated with Py.TsOH (0.014 g, 0.05 
mmol) to give 0.101 g (70%) of 21a as a colorless wax. Rf (Et2O/hexane 1:1): 0.13. IR 
(CHCl3): 3620w, 3350w, 3060w, 3005m, 2930s, 2860m, 1655m, 1625s, 1505s, 1480s, 
1400m, 715m, 700m. 1H-NMR (300 MHz, CDCl3): 8.01 (br. s, NH); 7.75–7.70 (m, 2 
arom. H); 7.50–7.35 (m, 3 arom. H); 7.20–7.15 (m, 3 arom. H); 7.00–6.95 (m, 2 arom. 
H); 4.12, 3.22 (AB, J = 14.3, PhCH2); 3.61 (t, J = 6.5, CH2O); 3.50–2.80 (br. s, 1 H, 
Me2N); 2.05–1.90 (m, 1 H); 1.70–1.45 (m, 3 H); 1.45–1.20 (m, 12 H). 13C-NMR (50 
MHz, CDCl3): 171.0 (s, O=CNMe2); 165.7 (s, PhC=O); 136.4, 135.4  (2s, 2 arom. C); 
131.0 (d, arom. CH); 129.4 (d, 2 arom. CH); 128.3 (d, 2 arom. CH); 127.9 (d, 2 arom. 
CH); 126.6 (d, 2 arom. CH); 126.5 (d, arom. CH); 65.9 (s, C–N); 62.5 (t, CH2O); 38.6 
(t, PhCH2); 38.4 (q, Me2N); 33.5, 32.5, 29.3, 29.2, 29.1, 29.0, 25.5, 24.1 (8t, 8 CH2). 
CI-MS (isobutane): 439 (72, [M+1]+), 394 (100), 366 (8), 347 (22), 317 (6).  
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4.2. N-[1-Benzyl-1-(N,N-dimethylcarbamoyl)-12-hydroxydodecyl]benzamide 
(21b). According to GP 3 a soln. of 20b (0.130 g, 0.24 mmol) in EtOH (3 ml) was 
treated with Py.TsOH (0.010 g, 0.04 mmol) to give 0.080 g (71%) of 21b as a 
colorless wax. Rf (Et2O/hexane 1:1): 0.17. IR (CHCl3): 3620w, 3350w, 3005m, 2930s, 
2860m, 1655m, 1625s, 1505s, 1480s, 1400m, 700m. 1H-NMR (300 MHz, CDCl3): 
8.00 (br. s, NH); 7.75–7.70 (m, 2 arom. H); 7.50–7.35 (m, 3 arom. H); 7.20–7.15 (m, 3 
arom. H); 7.05–7.00 (m, 2 arom. H); 4.12, 3.22 (AB, J = 14.3, PhCH2); 3.63 (t, J = 
6.6, CH2O); 3.45–2.85 (br. s, Me2N); 2.05–1.90 (m, 1 H); 1.63 (br. s, OH); 1.60–1.50 
(m, 2 H); 1.45–1.00 (m, 17 H). 13C-NMR (50 MHz, CDCl3): 171.0 (s, O=CNMe2); 
165.7 (s, PhC=O); 136.4, 135.5 (2s, 2 arom. C); 131.0 (d, arom. CH); 129.4 (d, 2 
arom. CH); 128.3 (d, 2 arom. CH); 127.9 (d, 2 arom. CH); 126.7 (d, 2 arom. CH); 
126.6 (d, arom. CH); 66.1 (s, C–N); 62.6 (t, CH2O); 38.7 (t, PhCH2); 38.4 (q, Me2N); 
33.6, 32.6 (2t, 2 CH2); 29.3, 29.28, 29.2 (3t, 6 CH2); 25.6, 24.2 (2t, 2 CH2). CI-MS 
(isobutane): 467 (94, [M+1]+), 422 (100), 375 (8). Anal. calc. for C29H42N2O3 
(466.67): C 74.64, H 9.07, N 6.00; found: C 74.23, H 9.09, N 6.16. 
5. Lactone-Formation via Direct Amide Cyclization of Diamides 21. 5.1. N-(3-
Benzyl-2-oxo-1-oxacyclododec-3-yl)benzamide (23a). The reaction of 21a (0.085 g, 
0.19 mmol) in toluene (101 ml) with HCl gas according to GP 4 gave 23a (0.032 g, 
43%) as colorless crystals and 4-benzyl-4-(9-hydroxynonyl)-2-phenyl-1,3-oxazol-
5(4H)-one (0.041 g, 55%). 
Data of 23a: Rf (Et2O/hexane 1:1): 0.47. M.p. 137.5–138.5°. IR (CHCl3): 
3410w, 3060w, 3010w, 2935m, 1725m, 1660s, 1520s, 1490s, 1470m, 1455m, 1350m, 
1235m, 1200m, 720s, 705s, 670s. 1H-NMR (300 MHz, CDCl3): 7.70–7.65 (m, 2 arom. 
H); 7.50–7.35 (m, 3 arom. H); 7.20–7.15 (m, 3 arom. H); 7.05–7.00 (m, 2 arom. H, 
NH); 4.80–4.75, 4.00–3.90 (2m, CH2O); 3.96, 3.22 (AB, J = 13.5, PhCH2); 2.85–2.75, 
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2.25–2.05 (2m, 2 H); 1.70–1.60 (m, 3 H); 1.55–0.90 (m, 11 H). 13C-NMR (50 MHz, 
CDCl3): 173.9 (s, C=O); 166.6 (s, NC=O); 136.6, 135.3  (2s, 2 arom. C); 131.4 (d, 
arom. CH); 129.6 (d, 2 arom. CH); 128.6 (d, 2 arom. CH); 128.2 (d, 2 arom. CH); 
126.8 (d, 3 arom. CH); 67.2 (s, C(3)); 65.5 (t, CH2O); 40.5 (t, PhCH2); 32.8, 26.3 (2t, 
2 CH2); 25.8 (t, 2 CH2); 22.9, 22.1, 21.4, 20.7 (4t, 4 CH2). CI-MS (isobutane): 395 
(100, [M+1]+), 303 (94). Anal. calc. for C25H31NO3 (393.53): C 76.30, H 7.94, N 3.56; 
found: C 76.28, H 7.98, N 3.42. 
Suitable crystals for the X-ray crystal-structure determination were grown 
from Et2O/CH2Cl2/hexane. 
Data of 4-Benzyl-4-(9-hydroxynonyl)-2-phenyl-1,3-oxazol-5(4H)-one: IR 
(CHCl3): 3620w, 3060w, 3010w, 2930s, 2860m, 1815s, 1660s, 1455m, 1320m, 
1290m, 1050m, 1025m, 980m, 700s. 1H-NMR (300 MHz, CDCl3): 7.90–7.80 (m, 2 
arom. H); 7.60–7.50 (m, 1 arom. H); 7.50–7.40 (m, 2 arom. H); 7.20–7.10 (m, 5 arom. 
H); 3.62 (t, J = 6.6, CH2O); 3.21, 3.14 (AB, J = 13.4, PhCH2); 2.05–1.95, 1.60–1.50 
(2m, 2 CH2); 1.25 (br. s, 6 CH2). 
5.2. N-(3-Benzyl-2-oxo-1-oxacyclotetradec-3-yl)benzamide (23b). The 
reaction of 21b (0.250 g, 0.54 mmol) in toluene (165 ml) with HCl gas according to 
GP 4 gave 23b (0.196 g, 86%) as colorless crystals. Rf (Et2O/hexane 1:1): 0.52. M.p. 
115.8–116.0°. IR (CHCl3): 3410w, 3020w, 3005w, 2935s, 2860m, 1725m, 1660s, 
1515s, 1485s, 1460m, 1345m, 1235m, 1200m, 700m. 1H-NMR (300 MHz, CDCl3): 
7.75–7.70 (m, 2 arom. H); 7.50–7.45 (m, 1 arom. H); 7.45–7.35 (m, 2 arom. H); 7.20–
7.15 (m, 3 arom. H); 7.07 (br. s, NH); 7.05–7.00 (m, 2 arom. H); 4.45 (td-like, J ≈ 
10.7, 2.2, 1 H of CH2O); 4.10–4.00 (m, 1 H of CH2O); 3.99, 3.16 (AB, J = 13.4, 
PhCH2); 2.86 (td-like, J ≈ 13.4, 4.5, 1 H); 2.00–1.95 (m, 1 H); 1.75–1.55 (m, 2 H); 
1.55–1.20 (m, 14 H); 1.20–0.95 (m, 2 H). 13C-NMR (50 MHz, CDCl3): 174.0 (s, 
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C=O); 166.5 (s, NC=O); 136.6, 135.4 (2s, 2 arom. C); 131.4 (d, arom. CH); 129.6 (d, 
2 arom. CH); 128.6 (d, 2 arom. CH); 128.2 (d, 2 arom. CH); 127.0 (d, 3 arom. CH); 
67.0 (s, C(3)); 65.0 (t, CH2O); 41.0 (t, PhCH2); 34.7, 27.9, 26.1, 25.9, 25.8, 24.1, 24.0, 
22.6, 22.5, 21.3 (10t, 10 CH2). CI-MS (isobutane): 422 (100, [M+1]+), 330 (13). Anal. 
calc. for C27H35NO3 (421.58): C 76.93, H 8.37, N 3.32; found: C 76.82, H 8.21, N 
3.36. 
Suitable crystals for the X-ray crystal-structure determination were grown 
from Et2O/CH2Cl2/hexane. 
6. Lactone-Formation via Ring Transformations of Oxazolones 25. 6.1. N-(3-
Benzyl-2-oxo-1-oxacyclopentadec-3-yl)benzamide (23c). Treatment of a soln. of 25c 
(0.208 g, 0.35 mmol) in toluene (190 ml) with TBAF (0.194 g, 0.62 mmol) according 
to GP 5 gave 23c (0.108 g, 65%) as colorless crystals9). Rf (Et2O/hexane 1:1): 0.55. 
M.p. 120.0–121.6°. IR (CHCl3): 3410w, 3060w, 3010w, 2935s, 2860m, 1725m, 1660s, 
1515s, 1487s, 1455m, 1390m, 1347m, 1285m, 1240m, 1200m, 705s. 1H-NMR (300 
MHz, CDCl3): 7.75–7.65 (m, 2 arom. H); 7.50–7.45 (m, 1 arom. H); 7.45–7.40 (m, 2 
arom. H); 7.20–7.15 (m, 3 arom. H); 7.05–7.00 (m, 2 arom. H, NH); 4.60–4.50, 4.10–
4.00 (2m, CH2O); 3.95, 3.16 (AB, J = 13.4, PhCH2); 2.85–2.80, 2.10–1.95 (2m, 2 H); 
1.80–1.60 (m, CH2); 1.50–1.05 (m, 9 CH2). CI-MS (isobutane): 436 (100, [M+1]+), 
344 (7). Anal. calc. for C28H37NO3 (435.61): C 77.20, H 8.56, N 3.22; found: C 77.08, 
H 8.54, N 3.16. 
                                                 
9) In an experiment with incomplete transformation of 25c (0.200 g, 0.36 mmol), in 
addition to 0.055 g (35%) of 23c was obtained 4-benzyl-4-(12-hydroxydodecyl)-
2-phenyl-1,3-oxazol-5(4H)-one (0.068 g, 43%). 
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Suitable crystals for the X-ray crystal-structure determination were grown 
from Et2O/CH2Cl2/hexane. 
6.2. N-(3-Benzyl-2-oxo-1-oxacyclotetradec-3-yl)benzamide (23b). Treatment 
of a soln. of the mixture 25b/26b (0.200 g, 0.37 mmol, i.e., 0.180 g, 0.34 mmol 25b) 
in toluene (213 ml) with TBAF (0.221 g, 0.70 mmol) according to GP 5 gave 23b 
(0.099 g, 69%) as colorless crystals (see 5.2). 
6.3. N-(3-Benzyl-2-oxo-1-oxacyclotridec-3-yl)benzamide (23d). Treatment of a 
soln. of the mixture 25d/26d (0.199 g, 0.38 mmol, i.e., 0.189 g, 0.36 mmol 25d) in 
toluene (189 ml) with TBAF (0.212 g, 0.67 mmol) according to GP 5 gave 23d (0.075 
g, 51%) as colorless crystals. Rf (Et2O/hexane 1:1): 0.49. M.p. 139.5–140.5°. IR 
(CHCl3): 3410w, 3060w, 3000w, 2930s, 2860m, 1720s, 1660s, 1515s, 1485s, 1460m, 
1385m, 1345m, 1285m, 1250m, 1195m, 700m. 1H-NMR (300 MHz, CDCl3): 7.75–
7.70 (m, 2 arom. H); 7.50–7.45 (m, 1 arom. H); 7.45–7.35 (m, 2 arom. H); 7.20–7.15 
(m, 3 arom. H); 7.05–7.00 (m, 2 arom. H, NH); 4.65 (ddd, J = 10.8, 9.3, 3.2, 1 H of 
CH2O); 4.03 (ddd, J = 10.9, 4.9, 3.3, 1 H of CH2O); 3.96, 3.18 (AB, J = 13.5, PhCH2); 
2.85–2.75, 2.15–2.05 (2m, 2 H); 1.80–1.50 (m, CH2); 1.40–1.05 (m, 7 CH2). 13C-NMR 
(50 MHz, CDCl3): 173.9 (s, C=O); 166.5 (s, NC=O); 136.5, 135.3 (2s, 2 arom. C); 
131.4 (d, arom. CH); 129.6 (d, 2 arom. CH); 128.8 (d, arom. CH); 128.5 (d, 2 arom. 
CH); 128.1 (d, 2 arom. C); 126.8 (d, 2 arom. CH); 67.0 (s, C(3)); 66.2 (t, CH2O); 40.9 
(t, PhCH2); 34.4, 27.9 (2t, 2 CH2); 26.6 (t, 2 CH2); 25.6, 24.9, 24.5, 24.0, 21.6 (5t, 5 
CH2). CI-MS (isobutane): 408 (100, [M+1]+). Anal. calc. for C26H33NO3 (407.56): C 
76.62, H 8.16, N 3.44; found: C 76.88, H 8.09, N 3.53. 
Suitable crystals for the X-ray crystal-structure determination were grown 
from Et2O/CH2Cl2/hexane. 
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6.4. N-(3-Benzyl-2-oxo-1-oxacycloundec-3-yl)benzamide (23e). Treatment of a 
soln. of the mixture 25e/26e (0.348 g, 0.70 mmol, i.e., 0.331 g, 0.67 mmol 25e) in 
toluene (373 ml) with TBAF (0.383 g, 1.21 mmol) according to GP 5 gave 23e (0.026 
g, 10%) as colorless crystals. Rf (Et2O/hexane 1:1): 0.49. M.p. 150.5–151.5°. IR 
(CHCl3): 3410w, 3050w, 3000w, 2940m, 2930m, 2855w, 1720s, 1660s, 1530s, 1485s, 
1470m, 1395m, 1385m, 1360m, 1340m, 1230m, 1195m, 700w. 1H-NMR (300 MHz, 
CDCl3): 7.75–7.70 (m, 2 arom. H); 7.50–7.45 (m, 1 arom. H); 7.45–7.40 (m, 2 arom. 
H); 7.20–7.15 (m, 3 arom. H); 7.08 (br. s, NH); 7.00–6.95 (m, 2 arom. H); 4.80 (td-
like, J ≈ 10.8, 1.3, 1 H of CH2O); 4.00 (ddd, J = 11.2, 5.2, 1.8, 1 H of CH2O); 3.90, 
3.10 (AB, J = 13.4, PhCH2); 3.00–2.90, 2.15–2.05 (2m, 2 H); 1.95–1.85 (m, 1 H); 
1.70–1.50 (m, 5 H); 1.35–1.15 (m, 6 H). 13C-NMR (50 MHz, CDCl3): 174.0 (s, C=O); 
166.6 (s, NC=O); 136.3, 135.3 (2s, 2 arom. C); 131.3 (d, arom. CH); 129.5 (d, 2 arom. 
CH); 128.5 (d, 2 arom. CH); 128.1 (d, 2 arom. CH); 126.8 (d, 3 arom. CH); 67.0 (s, C   
(3)); 66.1 (t, CH2O); 41.2 (t, PhCH2); 30.6, 25.6, 25.2, 25.0, 23.9, 21.4, 20.3 (7t, 7 
CH2). CI-MS (isobutane): 380 (100, [M+1]+), 289 (18), 105 (53). Anal. calc. for 
C24H29NO3 (379.51): C 75.96, H 7.70, N 3.69; found: C 75.88, H 7.93, N 3.53. 
Suitable crystals for the X-ray crystal-structure determination were grown 
from Et2O/CH2Cl2/hexane. 
6.5. N-(3-Benzyl-2-oxo-1-oxacyclodec-3-yl)benzamide (23f). Treatment of a 
soln. of the mixture 25f/26f (0.267 g, 0.56 mmol, i.e., 0.227 g, 0.47 mmol 25f) in 
toluene (295 ml) with TBAF (0.307 g, 0.97 mmol) according to GP 5 gave 23f (0.034 
g, 20%) as colorless crystals. Rf (Et2O/hexane 1:1): 0.43. M.p. 85.0–87.4°. IR 
(CHCl3): 3405s, 3240w, 3060w, 3020w, 3005w, 2940w, 2860w, 1720m, 1660s, 1520s, 
1490s, 1470m, 1455m, 1390m, 1370m, 1240w, 705w. 1H-NMR (300 MHz, CDCl3): 
7.75–7.70 (m, 2 arom. H); 7.50–7.45 (m, 1 arom. H); 7.45–7.35 (m, 2 arom. H); 7.20–
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7.15 (m, 3 arom. H); 7.03 (br. s, NH); 7.00–6.95 (m, 2 arom. H); 4.83 (ddd, J ≈ 12.4, 
5.3, 3.0, 1 H of CH2O); 4.15–4.05 (m, 1 H of CH2O); 3.93, 3.05 (AB, J = 13.5, 
PhCH2); 3.00–2.95, 2.40–2.30 (2m, 2 H); 2.20–2.05 (m, 1 H); 1.85–1.25 (m, 8 H); 
1.05–0.85 (m, 1 H). 13C-NMR (50 MHz, CDCl3): 174.2 (s, C=O); 166.7 (s, NC=O); 
136.0, 135.4 (2s, 2 arom. C); 131.3 (d, arom. CH); 129.6 (d, 2 arom. CH); 128.5 (d, 2 
arom. CH); 128.1 (d, 2 arom. CH); 126.8 (d, 3 arom. CH); 68.0 (t, CH2O); 65.5 (s, 
C(3)); 41.5 (t, PhCH2); 29.9, 25.8, 24.9, 23.8, 23.1, 22.2 (6t, 6 CH2). EI-MS: 365 (5, 
M+), 274 (100), 105 (83), 91 (29), 77 (63). Anal. calc. for C23H27NO3 (365.48): C 
75.58, H 7.45, N 3.83; found: C 75.56, H 7.63, N 3.97. 
Suitable crystals for the X-ray crystal-structure determination were grown 
from Et2O/CH2Cl2/hexane. 
6.6. N-(3-Benzyl-2-oxo-1-oxacyclonon-3-yl)benzamide (23g). Treatment of a 
soln. of the mixture 25g/26g (0.172 g, 0.37 mmol, i.e., 0.160 g, 0.23 mmol 25g) in 
toluene (200 ml) with TBAF (0.210 g, 1.21 mmol) according to GP 5 gave 23g (0.075 
g, 51%) as colorless crystals. Rf (Et2O/hexane 1:1): 0.56. M.p. 107.0–111.0°. IR 
(CHCl3): 3410w, 3000m, 2930m, 2855w, 1730s, 1660s, 1515s, 1485s, 1460m, 1380m, 
1345m, 1290m, 1240m, 1195s, 1085m, 970m, 925m, 880m, 700m. 1H-NMR (300 
MHz, CDCl3): 7.70–7.65 (m, 2 arom. H); 7.50–7.45 (m, 1 arom. H); 7.45–7.35 (m, 2 
arom. H); 7.25–7.15 (m, 3 arom. H); 7.15–7.05 (m, 2 arom. H); 6.83 (br. s, NH); 
4.85–4.75 (m, 1 H of CH2O); 4.15 (dt, J = 10.8, 6.7, 1 H of CH2O); 3.81, 3.37 (AB, J 
= 13.6, PhCH2); 2.65–2.55 (m, 1 H); 2.13 (ddd, J ≈ 14.4, 6.6, 3.5, 1 H); 1.80–1.70 (m, 
2 H); 1.70–1.55 (m, 2 H); 1.55–1.30 (m, 4 H). CI-MS (isobutane): 352 (100, [M+1]+). 
Anal. calc. for C22H25NO3 (351.45): C 75.19, H 7.17, N 3.99; found: C 74.92, H 7.42, 
N 4.23. 
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6.7. N-(3-Benzyl-3,4,5,6-tetrahydro-2-oxo-2H-pyran-3-yl)benzamide (23h). 
Treatment of a soln. of the mixture 25h/26h (0.181 g, 0.43 mmol, i.e., 0.112 g, 0.26 
mmol 25h) in toluene (230 ml) with TBAF (0.238 g, 0.75 mmol) according to GP 5 
gave 23h (0.069 g, 86%) as colorless crystals and 4-benzyl-5-[(3-hydroxypropyl)oxy]-
2-phenyl-1,3-oxazole (0.016 g, 30% with respect to 26h).  
Data of 23h: Rf (Et2O/hexane 1:1): 0.48. M.p. 155.7–156.7°. IR (CHCl3): 
3440w, 3060w, 3010m, 2970w, 2860w, 1730s, 1660s, 1510s, 1480s, 1455m, 1400m, 
1280m, 1260s, 1170s, 1120m, 1100m, 1075m, 975m, 705m. 1H-NMR (300 MHz, 
CDCl3): 7.70–7.65 (m, 2 arom. H); 7.55–7.50 (m, 1 arom. H); 7.50–7.30 (m, 5 arom. 
H); 7.25–7.20 (m, 2 arom. H); 6.09 (br. s, NH); 4.65–4.55, 4.45–4.35 (2m, CH2O); 
3.52, 3.16 (AB, J = 13.3, PhCH2); 2.45–2.40 (m, CH2); 1.90–1.80 (m, CH2). 13C-NMR 
(50 MHz, CDCl3): 172.4 (s, C=O); 166.6 (s, NC=O); 134.3, 133.6 (2s, 2 arom. C); 
131.7 (d, arom. CH); 130.2 (d, 2 arom. CH); 128.7 (d, 2 arom. CH); 128.4 (d, 2 arom. 
CH); 127.6 (d, arom. C); 126.9 (d, 2 arom. CH); 69.8 (t, CH2O); 58.9 (s, C(3));  43.4 
(t, PhCH2); 31.2, 21.5 (2t, 2 CH2). CI-MS (isobutane): 310 (100, [M+1]+). Anal. calc. 
for C19H19NO3 (309.37): C 73.77, H 6.19, N 4.53; found: C 74.02, H 6.38, N 4.65. 
Data of 4-Benzyl-5-[(3-hydroxypropyl)oxy]-2-phenyl-1,3-oxazole: 1H-NMR 
(300 MHz, CDCl3): 7.90–7.85 (m, 2 arom. H); 7.50–7.30 (m, 3 arom. H); 7.30–7.20 
(m, 4 arom. H); 7.20–7.10 (m, 1 arom. H); 4.19 (t, J = 6.1, CH2O); 3.80 (s, PhCH2); 
3.72 (t, J = 6.0, CH2O); 1.89 (pent, J = 6.0, CH2); 1.80–1.40 (br. s, OH). 
6.8. N-(3-Benzyl-2,3,4,5-tetrahydro-2-oxofuran-3-yl)benzamide (23i). 
Treatment of a soln. of 25i (0.109 g, 0.27 mmol) in toluene (140 ml) with TBAF 
(0.151 g, 0.48 mmol) according to GP 5 gave 23i (0.080 g, 100%) as colorless 
crystals. Rf (Et2O/hexane 1:1): 0.50. M.p. 170.2–171.2°. IR (CHCl3): 3420w, 3070w, 
3020w, 2930w, 2860w, 1775s, 1670s, 1515s, 1485s, 1290m, 1185m, 1165m, 1025m, 
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710m. 1H-NMR (300 MHz, CDCl3): 7.75–7.70 (m, 2 arom. H); 7.60–7.50 (m, 1 arom. 
H); 7.50–7.40 (m, 2 arom. H); 7.40–7.30 (m, 3 arom. H); 7.30–7.25 (m, 2 arom. H); 
6.63 (br. s, NH); 4.36 (td, J = 9.3, 2.4, 1 H of CH2O); 3.61 (td, J = 9.5, 7.3, 1 H of 
CH2O); 3.33, 3.25 (AB, J = 13.2, PhCH2); 2.87 (ddd, J = 13.4, 7.3, 2.5, 1 H); 2.77 (td, 
J = 9.7, 13.4, 1 H). 13C-NMR (50 MHz, CDCl3): 177.0 (s, C=O); 166.8 (s, NC=O); 
133.8, 133.3 (2s, 2 arom. C); 132.0 (d, arom. CH); 130.0 (d, 2 arom. CH); 128.8 (d, 2 
arom. CH); 128.6 (d, 2 arom. CH); 127.8 (d, arom. CH); 127.0 (d, 2 arom. CH); 65.9 
(t, CH2O); 60.1 (s, C(3));  41.6 (t, PhCH2); 33.2 (t, CH2). CI-MS (isobutane): 296 
(100, [M+1]+), 250 (21). Anal. calc. for C18H17NO3 (295.34): C 73.20, H 5.80, N 4.74; 
found: C 73.13, H 5.69, N 4.62. 
7. X-Ray Crystal-Structure Determination of 23a–f (see Table 3 and Figs. 1 
and 2)10). The measurements for 23a, b, d–f were made on a Nicolet-R3 
diffractometer using graphite-monochromated MoKα radiation (λ  0.71073 Å), those 
for 23c on a Rigaku AFC5R diffractometer using graphite-monochromated MoKα 
radiation and a 12 kW rotating anode generator. The intensities were corrected for 
Lorentz and polarization effects, but not for absorption. Equivalent reflections were 
merged. The data collection and refinement parameters are given in Table 3, and 
                                                 
10) CCDC-1447397–1447402 contain the supplementary crystallographic data for 
this paper. These data can be obtained free of charge from The Cambridge 
Crystallographic Data Centre via www.ccdc.cam.ac.uk/getstructures. 
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views of the molecules are shown in Figs. 1–311). The structures were solved by 
direct methods using SHELXS86 [23], which revealed the positions of all non-H-
atoms. The benzyl group of 23a is disordered over two conformations as a result of a 
small rotation about the C(2)–C(19) bond. Two sets of positions were defined for the 
atoms of the Ph ring and the site occupation factor of the major conformation refined 
to 0.510(12). Similarity restraints were applied to the chemically equivalent bond 
lengths and angles involving all disordered C-atoms, while neighboring atoms within 
and between each disordered conformation were restrained to have similar atomic 
displacement parameters. In the case of 23c, the 15-membered ring is disordered in 
such a way that both enantiomers are present at the same site. In this arrangement all 
atoms occupy identical positions, with the only detectable difference being the 
presence of the lactone carbonyl O-atom of the 15-membered ring on both sides of the 
quaternary C-atom. This requires that O(1) and C(4) are similarly disordered across 
common sites. Atoms C(4) and O(1A) were constrained to have identical atomic 
coordinates and atomic displacement parameters. Similar constraints were applied to 
C(4A) and O(1). The site occupation factors of the disordered sites was refined and 
converged at 0.912(4) for the major conformer. For all compounds, the non-H-atoms 
were refined anisotropically. The amide H-atoms were placed in the positions 
indicated by difference electron density maps and their positions were allowed to 
refine together with individual isotropic displacement parameters. All remaining H-
atoms were placed in geometrically calculated positions and refined by using a riding 
model where each H-atom was assigned a fixed isotropic displacement parameter with 
                                                 
11)  For 23a,b the obtainable crystal quality was sub-optimal and this is reflected in 
the quality of the crystal structure refinement results, although both structures 
are quite unambiguous. 
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a value equal to 1.2Ueq of its parent C-atom. The refinement of each structure was 
carried out on F2 by using full-matrix least-squares procedures, which minimized the 
function Σw(Fo2 – Fc2)2. A correction for secondary extinction was applied in the cases 
of 32c–e. In the cases of 23b and 23d, twenty and one reflection, respectively, whose 
intensities were considered to be extreme outliers, were omitted from the final 
refinement. Neutral atom scattering factors for non-H-atoms were taken from [24], 
and the scattering factors for H-atoms were taken from [25].  Anomalous dispersion 
effects were included in Fc [26]; the values for ƒ’ and ƒ” were those of [27]. The 
values of the mass attenuation coefficients are those of [28]. The SHELXL97 program 
[29] was used for all calculations. 
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Legends 
 
Table 1. Alkylations of 1,3-Oxazol-5(4H)-one 15 with ω-{[(tert-
Butyl)dimethylsilyl]oxy}-1-iodoalkanes 24a) (Scheme 4). 
 
Table 2. Synthesis of Lactones 23 via direct Ring-Transformation of Oxazolones 25a) 
(Scheme 4) 
 
Table 3.  Crystallographic Data for Lactones 23a–23f   
 
 
 
Fig. 1. ORTEP Plot [18] of the molecular structures of the 12- and 14-membered 
lactones 23a (major conformation) and 23b (50% probability ellipsoids, arbitrary 
numbering of atoms) 
 
Fig. 2. ORTEP Plot [18] of the molecular structure of the 15-membered lactone 23c 
(major conformation; 50% probability ellipsoids, arbitrary numbering of atoms) 
 
Fig. 3. ORTEP Plots [18] of the molecular structures of the lactones 23d–23f (50% 
probability ellipsoids, arbitrary numbering of atoms) 
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Table 1. Alkylations of 1,3-Oxazol-5(4H)-one 15 with ω-{[(tert-
Butyl)dimethylsilyl]oxy}-1-iodoalkanes 24a) (Scheme 4). 
 
 
Iodoalkane  
24 
n Products   Yield [%]b) Ratio 
Oxazolone 25 Oxazole 26 Esters 27 + 28 25/26 25/26 
b 
c 
d 
e 
f 
g 
h 
i 
11 
12 
10 
8 
7 
6 
3 
2 
b 
c 
d 
e 
f 
g 
h 
i (61%) 
b 
- 
d 
e 
f 
g 
h 
i (10%) 
- 
c (14%) 
d (9%) 
- 
f (14%)c) 
g (13%)c) 
h (16%)c) 
- 
52 
35 
60 
58 
42 
30 
40 
71 
9:1 
 
10:1 
16:2 
23:4 
20:3 
13:4 
6:1 
 
a) LDA, THF/HMPT (ca. 2:1 to 4:1), –78° to +15°. 
b) Yield of isolated products. 
c) Only butyl ester of type 27.  
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Table 2. Synthesis of Lactones 23 via direct Ringtransformation of Oxazolones 25a) 
(Scheme 4) 
 
Oxazolone 25 n Lactone 23 Ringsize [n + 3] Yield [%]b) 
b 
c 
d 
e 
f 
g 
h 
i 
11 
12 
10 
8 
7 
6 
3 
2 
b 
c 
d 
e 
f 
g 
h 
i 
14 
15 
13 
11 
10 
9 
6 
5 
69 
65c) 
51 
10 
20 
51 
86 
100 
 
a) Ca. 1.9 mM solution of 25 in toluene, ca. 1.7 equiv. of TBAF.3 H2O, 90–110°, 
bubbling HCl gas through the solution for 1.5–2 h. 
b) Yield of isolated product; calculated on the amount of 25 in the used mixture of 
25/26. 
c) In one experiment (ca. 1 h), the reaction was not complete. In addition to lactone 
23c (35%), 43% of the corresponding deprotected 1,3-oxazol-5(4H)-one was isolated. 
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Table  3. Crystallographic Data for Compounds 23a – 23f   
  
23a 
 
23b 
 
23c 
 
23d 
 
23e 
 
23f 
 
Crystallized from 
Empirical formula 
Formula weigth 
Crystal color, habit 
Crystal dimensions [mm] 
Temperature [K] 
Crystal system 
Space group 
Z 
Reflections for cell determination 
2θ range for cell determination [°] 
Unit cell parameter         a [Å] 
                                        b [Å] 
                                        c [Å] 
                                       β [°] 
                                       V [Å3] 
Dx [g cm–3] 
µ(MoKα) [mm–1] 
Scan type 
2θ(max) [°] 
Total reflections measured 
Symmetry independent reflections 
Reflections with I>2σ(I) 
Reflections used in refinement  
Parameters refined; restraints 
Final  R(F)  [I>2σ (I) reflections] 
          wR(F2)  (all data) 
Weighting parameters [a; b]a) 
Goodness of fit 
Secondary extinction coefficient 
Final ∆max/σ 
∆ρ (max; min) [e Å–3] 
 
Et2O/hexane 
C25H31NO3 
393.52 
colorless, prism 
0.16 × 0.38 × 0.44 
213(1) 
monoclinic 
P21/c 
4 
25 
20–22 
17.008(4) 
8.391(2) 
15.683(2) 
100.25(2) 
2202.5(9) 
1.187 
0.077 
ω 
50 
4655 
3874 
1830 
3874 
321; 181 
0.0809 
0.2540 
0.0916; 2.1728 
1.034 
- 
0.036 
0.40; –0.17 
 
 
Et2O/hexane 
C27H35NO3 
421.56 
colorless, prism 
0.30 × 0.32 × 0.54 
295(1) 
monoclinic 
P21/c 
4 
17 
24–30 
8.828(3) 
15.678(5) 
17.963(5) 
96.29(3) 
2471(1) 
1.133 
0.073 
ω 
50 
4997 
4323 
1946 
4303 
284; 0 
0.1152 
0.4048 
0.2; 0 
1.207 
- 
0.001 
0.44; –0.51 
 
Et2O/hexane 
C28H37NO3 
435.59 
colorless, needle 
0.12 × 0.15 × 0.40 
173(1) 
orthorhombic 
Pbca 
8 
25 
27–37 
18.147(5) 
26.831(5) 
10.054(5) 
90 
4896(3)  
1.182 
0.076 
ωθ 
55 
7177 
5601 
2818 
5601 
309; 0 
0.0613 
0.1503 
0.0476; 0 
1.003 
0.0013(4) 
0.001 
0.34; –0.22 
 
Et2O/hexane 
C26H33NO3 
407.53 
colorless, prism 
0.24 × 0.36 × 0.43 
213(1) 
monoclinic 
P21/c 
4 
25 
27–30 
17.917(2) 
8.205(1) 
16.168(3) 
107.32(1) 
2269.1(6) 
1.193 
0.072 
ω 
55 
6604 
5227 
3082 
5226 
276; 0 
0.0496 
0.1168 
0.2293; 0 
1.043 
0.0046(8) 
0.001 
0.16; –0.16 
 
 
Et2O/hexane 
C24H29NO3 
379.50 
colorless, prism 
0.25 × 0.42 × 0.45 
213(1) 
monoclinic 
P21/c 
4 
25 
28–33 
10.836(1) 
9.216(1) 
21.011(3) 
97.47(1) 
2080.3(5) 
1.112 
0.079 
ω 
55 
4821 
 
2570 
3778 
258; 0 
0.0421 
0.1014 
0.0382; 0.4213 
1.023 
0.0049(7) 
0.001 
0.17; –0.13 
 
Et2O/hexane 
C23H27NO3 
365.46 
colorless, prism 
0.34 × 0.40 × 0.45 
213(1) 
monoclinic 
P21/c 
4 
25 
30–32 
9.990(1) 
19.808(3) 
9.968(2) 
99.89(1) 
1943.4(5) 
1.249 
0.082 
ω 
55 
5106 
 
2883 
4451 
248; 0 
0.0498 
0.1154 
0.0368; 0.4747 
1.016 
- 
0.001 
0.19; –0.19 
 
a) w–1 = σ 2(Fo2) + (aP)2 + bP  where P = (Fo2 + 2 Fc2)/3 
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Scheme 1 
 
 
 
 
Scheme 2 
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Scheme 3 
 
 
 
 
Scheme 4 
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Formulae 19, 27c and 28c 
 
 
 
 
 
Figure 1 
 
23a                                                                  23b 
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 Figure 2 
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Figure 3 
23d           23e 
     
 
                                        23f 
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